Oral formulations of cannabinoids

SEDDS formulations using glycerol esters and polyethylene glycol-containing fatty acid esters address the dissolution and bioavailability challenges of cannabinoids, enhancing absorption and plasma concentration consistency.

SA1120261009A1Pending Publication Date: 2026-10-05NW MICELLE THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
SA1120261009
Authority / Receiving Office
SA · SA
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-02-02
Publication Date
2026-10-05

AI Technical Summary

Technical Problem

Existing formulations struggle to effectively dissolve therapeutic agents, particularly lipophilic compounds like cannabinoids, and enhance their bioavailability, leading to inconsistent absorption and plasma concentration profiles.

Method used

Self-emulsifying drug delivery systems (SEDDS) comprising glycerol esters of fatty acids and polyethylene glycol-containing fatty acid esters are used to create colloidal dispersions that enhance the solubility and absorption of cannabinoids, including cannabidiol, by forming emulsions in the gastrointestinal tract.

Benefits of technology

SEDDS formulations improve gastrointestinal absorption and systemic exposure of cannabinoids, providing consistent plasma concentration profiles and increased bioavailability, even without sesame oil or ethanol.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0745D35F-A48A-4544-8A34-18DCF1FF61B1
    Figure 0745D35F-A48A-4544-8A34-18DCF1FF61B1
  • Figure 19498B54-266F-43BA-9DC4-D0287B0D1A69
    Figure 19498B54-266F-43BA-9DC4-D0287B0D1A69
  • Figure 1E705EE2-2EB6-44FE-8863-1EF2CE43763F
    Figure 1E705EE2-2EB6-44FE-8863-1EF2CE43763F
Patent Text Reader

Abstract

The present invention concerns cannabinoid formulations that have advantages such as high drug loading and stability, and related methods for the manufacture and use of these formulations. Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

The current disclosure presents formulations for therapeutic agents. These formulations are effective in dissolving therapeutic agents, particularly those that are difficult to dissolve. They also effectively enhance the bioavailability of therapeutic agents while providing high concentrations. Furthermore, this disclosure presents formulations for therapeutic agents based on effective formulations for therapeutic agent delivery, especially oral administration. The disclosure also presents cannabinoid formulations, including cannabidiol (CBD) formulations, based on existing formulations. The formulations described effectively dissolve cannabinoids, including CBD, providing formulations with increased concentrations of cannabinoids while simultaneously offering enhanced bioavailability. Self-emulsifying drug delivery systems (SEDDS) are an example of advanced lipid-based formulations that can be used to enhance the absorption of cannabinoids, including cannabidiol (CBD). Simply put, a self-emulsifying drug delivery system is a homogeneous mixture of oils, surfactants, and / or co-solvents that spontaneously coalesce into a colloidal dispersion or emulsion when mixed with an aqueous medium, such as the gastrointestinal tract. Self-emulsifying drug delivery systems can meet the needs of cannabinoid formulations, including CBD, by increasing their apparent solubility and delivering high therapeutic doses. Definitions: While the following terms are thought to be well understood by a person of average skill in this field, the following definitions have been put in place to facilitate the explanation of the subject being revealed. The indefinite form refers to one or more of those entities; that is, it can refer to a collective noun. As such, the indefinite form, "one or more," and "at least one" are used interchangeably in this document. Furthermore, the use of definite and indefinite articles does not preclude the possibility of more than one element, unless the context clearly requires only one. The phrase “and / or,” as used here in the specification and in the safeguards, should be understood to mean “one or both” of the elements so attached, that is, elements that exist together in some cases and separately in others. Multiple elements listed by “and / or” should be interpreted in the same way, that is, “one or more” of the elements so attached. Other elements may optionally exist besides those specifically identified in the “and / or” phrase, whether or not they are related to those identified. Thus, as an example without limitation, the reference to “(a) and / or (b),” when used in conjunction with an open language such as “include,” could, in one implementation, refer to (a) only (with optional inclusion of elements other than (b)); in another implementation, it could refer to (b) only (with optional inclusion of elements other than (a)); in yet another implementation, it could refer to both (a) and (b) (with optional inclusion of other elements); and so on. As used here in the specifications and in the safeguards, the phrase "at least one item," when referring to a list of one or more items, should be understood to mean at least one item selected from any one or more items in the item list, but not necessarily including at least one item from each item specifically listed in the item list, nor excluding any groups of items in the item list. This definition also allows for the presence of items that may be optionally included, other than those specifically listed in the item list referred to by "at least one," whether or not they are related to those specified items.Thus, as a non-exclusive example, the phrase "at least one of (A) and (B)" (or, equivalently, "at least one of (A) or (B)," or, equivalently, "at least one of (A) and / or (B)), in one implementation model, could refer to at least one, with the possibility of including more than one, (A), without (B) (and the possibility of including elements other than (B)); in another implementation model, it could refer to at least one, which could optionally include more than one, (B), without (A) (and could include elements other than (A)); in yet another implementation model, it could refer to at least one, with the possibility of optionally including more than one, (A), and at least one, with the possibility of optionally including more than one, (B) (and the possibility of optionally including other elements); and so on. Throughout this application, the term "approximately" is used to indicate that the value includes the inherent error of the instrument or method used to determine the value, or the variance between the samples being measured. In some applied models, "approximately" means within 5% of the reported numerical value. When "approximately" is used in conjunction with a range or series of values, it applies to the endpoints of the range or each value included in the series, unless otherwise stated. As used in this document, the verb "to consist" as used in this description and in the protection elements and its conjugates is used in its non-exclusive sense to mean that elements following the word are included, but elements not specifically mentioned are not excluded. It is also noted that safeguards can be formulated to exclude any optional element. As such, this statement is intended to serve as a preliminary basis for the use of exclusive terms such as "solely," "only," "consisting of," and the like, in listing safeguards, or for the use of a "negative" restriction. A "study participant" is a living animal, especially a mammal, that can be treated with a pharmaceutical formulation described in this document. In some case studies, the study participant is a human. In some case studies, the study participant is a human child, adolescent, or adult. In some case studies, the study participant or patient is a non-human animal, including research animals such as mice, rats, pigs, dogs, rabbits, monkeys, other non-human primates, or goats. The term "formulation" as used in this document includes the term "composition." Accordingly, formulation may refer to a formulation containing one or more cannabinoids. Alternatively, formulation may refer to a formulation containing one or more cannabinoids, along with one or more pharmaceutically acceptable excipients. The term "active agent," as used in this document, refers to a medicinal substance (e.g., cannabinoid, or optionally cannabidiol) that produces a desired biological effect. It is understood that cannabidiol is an illustrative model of a cannabinoid, and that a cannabidiol formulation is an illustrative model of a cannabinoid formulation, as used in this document. The terms "cannabidiol" and "CBD" are used interchangeably in this document and refer to a molecule with the following structure. Furthermore, the active agents in the formulations described in this document include prodrugs and cannabidiol derivatives, as well as biologically and synthetically derived cannabidiol. Unless otherwise stated, all weight percentages (i.e., "weight percentage", "weight percentage", and "weight / weight percentage") referred to in this document are measured relative to the total weight of the formulation or microparticles, depending on the context. The term "dominant" as used in this document should be understood to mean that it constitutes a larger percentage by weight than any other component. For example, the dominant form of a fatty acid glycerol ester (such as monoglycerides) is the form that is present in greater quantities than any other form of the fatty acid glycerol ester. The term "dose," as used in this document, refers to the quantity of the formulation administered to the patient that contains a therapeutically effective amount of one or more cannabinoids. For example, a dose might be one tablet or one capsule containing a formulation disclosed in this document. The terms “treatment” and “cure,” as used in this document, refer to reducing the severity and / or frequency of symptoms, eliminating symptoms and / or the underlying cause, decreasing the likelihood of symptoms and / or the underlying cause occurring, and improving or repairing damage. Therefore, “treating” a patient with an effective agent, as defined in this document, includes suppressing a specific condition, disease, or disorder in a susceptible individual, as well as treating an individual experiencing clinical symptoms. As used in this document, "effective dose" refers to a quantity that covers both therapeutically effective and prophylactically effective amounts. As used in this document, "therapeutably effective dose" refers to the amount effective in achieving the desired therapeutic outcome. The amount varies... Therapeutically effective from a specific active ingredient, usually depending on factors such as the type and severity of the disorder or disease being treated, the patient's age, gender, and weight. Self-emulsifying drug delivery system assemblies The present disclosure presents formulations containing cannabinoids, including cannabidiol. In some application models, these formulations are self-emulsifying drug delivery systems (SDDSs). As used in this document, the terms "cannabinoid self-emulsifying drug delivery system formulation" and "cannabinoid self-emulsifying drug delivery system" are used interchangeably and refer to the self-emulsifying drug delivery system formulation described herein that contains cannabinoids. As used in this document, the terms "cannabidiol self-emulsifying drug delivery system formulation" and "cannabidiol self-emulsifying drug delivery system" are used interchangeably and refer to the self-emulsifying drug delivery system formulation described herein that contains cannabidiol. A self-emulsifying drug delivery system is a homogeneous mixture of oils, surfactants, solvents, and solvent / surfactant auxiliaries.Self-emulsifying drug delivery systems (SEDS) can be used to design formulations that enhance the absorption of highly lipophilic drugs, such as cannabinoids, after oral administration. SEDS spontaneously assemble to form a colloidal or emulsion dispersion when mixed with aqueous media, such as those found in the gastrointestinal tract. Furthermore, when the SEDS formulation is released into the intestinal lumen, it disperses to form a coarse, fine, or ultrafine emulsion, allowing the drug to remain in solution in the intestine. This avoids the dissolution step that often limits the absorption rate of hydrophobic drugs from the crystalline state. The use of SEDS typically results in improved bioavailability and / or a more consistent temporal pattern of intestinal absorption. A description of SEDS formulations can be found in C.W. Pouton, Advanced Drug Delivery Reviews 25: 47–58 (1997). In the context of cannabinoids, including cannabidiol, an emulsified drug delivery system has demonstrated the ability to improve systemic exposure compared to medium-chain triglyceride oil or lipid-free solutions (Cherniakovetal. Eur. J. Pharm. Sci. 2017, 109, 21–30; Knaubetal. Molecules. 2019, 24(16), 2967; Nakanoetal. Med. CannabisCannabinoids. 2019, 2(1), 35–42; Koketal. Eur. J. Pharm. Sci. 2022, 168, 106058; DePráetal. Int. J. Pharm. 2021, 609, 121159). It has also been reported that an emulsified drug delivery system formulation containing sesame oil generates a more predictable time curve for plasma concentrations compared to sesame oil as the sole carrier, although without a corresponding improvement in absorption (Izgelovetal. Eur. J. Pharm. Biopharm. 2020, 154, 108-115). The current findings also provide self-emulsifying drug delivery system formulations that offer better gastrointestinal absorption and systemic exposure to cannabinoids, including cannabidiol, following oral administration. In some of the applied models, these formulations do not contain sesame oil.In some applied models, these formulations do not contain ethanol. In some applied models, the current discovery provides cannabinoid structures, which include the following: Cannabinoids, preferably cannabidiol; One or more glycerol esters of fatty acids; and One or more fatty acid esters containing polyethylene glycol. In some applied models, the formulations consist of cannabinoids, for example, cannabidiol (CBD), in amounts greater than or equal to approximately 1% by weight. In other applied models, the formulations consist of cannabinoids in amounts greater than or equal to approximately 5%, greater than or equal to approximately 10%, greater than or equal to approximately 15%, greater than or equal to approximately 20%, greater than or equal to approximately 25%, greater than or equal to approximately 30%, greater than or equal to approximately 35%, greater than or equal to approximately 40%, greater than or equal to approximately 45%, greater than or equal to approximately 50%, or greater than or equal to approximately 55% by weight. In some applied models, the formulations consist of cannabinoids of less than or equal to about 70%, less than or equal to about 65%, less than or equal to about 60%, less than or equal to about 55%, less than or equal to about 50%, less than or equal to about 45%, less than or equal to about 40%, less than or equal to about 35%, less than or equal to about 35%, less than or equal to about 30%, or less than or equal to about 25% by weight.In some applied models, the compounds consist of cannabinoids in proportions ranging from approximately 1% to approximately 60% by weight. In other applied models, the compounds consist of cannabinoids in proportions ranging from approximately 10% to approximately 50% by weight. In other applied models, the compounds consist of cannabinoids in proportions ranging from approximately 20% to approximately 40% by weight, or from approximately 10% to approximately 60% by weight, or from approximately 20% to approximately 60% by weight, or from approximately 30% to approximately 60% by weight. In other applied models, the compounds consist of cannabinoids in amounts ranging from approximately 15%, or approximately 20%, or approximately 25%, or approximately 30%, or approximately 35%, or approximately 40%, or approximately 45%, or approximately 50% by weight. In some applied models, the formulations consist of cannabinoids, for example, cannabidiol (CBD), at approximately 20% by weight. In some applied models, the formulations consist of cannabinoids, for example, CBD, at approximately 30% by weight. In some applied models, the formulations consist of cannabinoids, for example, CBD, at approximately 40% by weight.In some applied models, the formulations consist of cannabinoids, for example, cannabidiol, within a percentage by weight range of any two of the percentages shown. For example, approximately 15% to approximately 40% by weight. In some applied models, the formulations consist of CBD in amounts greater than or equal to approximately 1% by weight. In other applied models, the formulations consist of CBD in amounts greater than or equal to approximately 5%, greater than or equal to approximately 10%, greater than or equal to approximately 15%, greater than or equal to approximately 20%, greater than or equal to approximately 25%, greater than or equal to approximately 30%, greater than or equal to approximately 35%, greater than or equal to approximately 40%, greater than or equal to approximately 45%, greater than or equal to approximately 50%, or greater than or equal to approximately 55% by weight. In some applied models, formulations consist of cannabidiol at a percentage less than or equal to approximately 70%, less than or equal to approximately 65%, less than or equal to approximately 60%, less than or equal to approximately 55%, less than or equal to approximately 50%, less than or equal to approximately 45%, less than or equal to approximately 40%, less than or equal to approximately 35%, less than or equal to approximately 35%, less than or equal to approximately 30%, or less than or equal to approximately 25% by weight.In some applied models, the formulations consist of CBD at a percentage ranging from approximately 1% to approximately 60% by weight. In some applied models, the formulations consist of CBD at a percentage ranging from approximately 10% to approximately 50% by weight. In some applied models, the formulations consist of CBD at approximately 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight. In some applied models, the formulations consist of CBD at approximately 20% by weight. In some applied models, the formulations consist of CBD at approximately 30% by weight. In some applied models, the formulations consist of CBD at approximately 40% by weight. In some applied models, the formulations consist of CBD within a percentage by weight range of any two of the percentages shown. For example, about 15% to about 40% of the weight. The present report describes self-emulsifying drug delivery systems for cannabinoids consisting of one or more glycerol esters of fatty acids and one or more fatty acid esters containing polyethylene glycol (PEG). In some application models, the formulations consist of one or more glycerol esters of fatty acids and one or more fatty acid esters containing PEG in proportions ranging from approximately 30:70% by weight to approximately 70:30% by weight. In other application models, the formulations consist of one or more glycerol esters of fatty acids and one or more fatty acid esters containing PEG in proportions ranging from approximately 40:60% by weight to approximately 60:40% by weight. In yet other application models, the formulations consist of one or more glycerol esters of fatty acids and one or more fatty acid esters containing polyethylene oxide in a proportion of approximately 50:50% by weight.In some applied models, one or more glycerol esters of fatty acids are made up of glyceryl oleates (e.g., Peceol®) and one or more polyethylene glycol-containing fatty acid esters are made up of polyethylene glycol-containing fatty acid esters derived from fatty acids, including saturated and unsaturated fatty acids containing eight (8) to twenty-two (22) carbon atoms (e.g., Gelucire 44 / 14®). The formulations of self-emulsifying drug delivery systems consist of glycerol esters of fatty acids. The cannabinoid self-emulsifying drug delivery system formulations described include one or more fatty acid glycerol esters. As used in this document, the term "fatty acid glycerol esters" refers to esters formed between glycerol and one or more fatty acids, including mono-, di-, and tri-esters (i.e., glycerides). Suitable fatty acids include saturated and unsaturated fatty acids containing between eight (8) and twenty-two (22) carbon atoms (i.e., C8-C22 fatty acids). In some application models, suitable fatty acids include C8-C18 fatty acids. Glycerol esters of beneficial fatty acids in formulations can be obtained from commercially available sources. A typical source of glycerol esters of fatty acids is the commercially available combination of mono-, di-, and tri-esters known as PECEOL® (Gattefosse, SaintPriestCedex, France), commonly referred to as "glycerol oleate" or "mono-glycerol oleate". PECEOL® functions as a solvent for lipophilic compounds and a bioavailability enhancer. In some applications, PECEOL® is a carrier containing long-chain fatty acids (C18:1) for the Lipid Structure Classification System (LFCS) of Type I (oily), Type II (self-emulsifying drug delivery system), and Type III (SMEDDS), associated with lymphatic absorption. In some applications, PECEOL® is an oil-based carrier used in oral or topical formulations. In some applications, PECEOL® has a viscosity of 220 mPa·s (20°C) and a lipophilic-hydrophilic equilibrium of 1. Its safety for use is inferred from its Generally Recognized As Safe (GRAS) status and prior use in approved pharmaceutical products. In some application models, when PECEOL® is used as a source of fatty acid glycerol esters in formulations, the fatty acid glycerol esters consist of approximately 32 to 52% by weight of fatty acid monoglycerides, approximately 30 to 50% by weight of fatty acid diglycerides, and approximately 5 to 20% by weight of fatty acid triglycerides. In other application models, PECEOL® consists of mono-, di-, and triglycerides of oleic acid (C18:1), with the monoester fraction being predominant. In some applied models, the detection formulations may include glycerol in an amount less than about 10% by weight. Self-emulsifying drug delivery system formulations composed of fatty acid esters containing polyethylene glycol As mentioned above, cannabidiol formulations include one or more polyethylene glycol-modified lipids (PEGs) such as PEG-containing phospholipids or one or more PEG-containing fatty acid esters, usually a combination of PEG-containing phospholipids or a combination of PEG-containing fatty acid esters. Accordingly, in one applied model, the cannabidiol formulations reported in the disclosure include (a) a cannabinoid, which could be cannabidiol; (b) one or more glycerol esters of fatty acids; and (c) one or more polyethylene glycol-containing fatty acid esters. As used in this document, the term "polyethylene glycol-containing fatty acid ester" refers to a fatty acid ester that includes a polyethylene glycol group (i.e., a PEG group) covalently linked to the fatty acid by an ester bond. Also as used in this document, the terms "polyethylene glycol," "polyethylene oxide," and "PEG" are used interchangeably. Polyethylene glycol-containing fatty acid esters include mono- and di-polyethylene glycol fatty acid esters. Suitable polyethylene glycol-containing fatty acid esters are derived from fatty acids, including saturated and unsaturated fatty acids, containing eight (8) to twenty-two (22) carbon atoms (i.e., the polyethylene glycol ester of the C8-C22 fatty acid).In some applied models, suitable polyethylene glycol-containing fatty acid esters are derived from fatty acids, including saturated and unsaturated fatty acids, containing eight (8) to eighteen (18) carbon atoms (i.e., polyethylene glycol ester of the C8-C18 fatty acid). In some applied models, suitable polyethylene glycol-containing fatty acid esters include the saturated C8-C18 fatty acids. The molecular weight of the polyethylene glycol group in a polyethylene glycol-containing fatty acid ester can be altered to improve the solubility of the therapeutic agent (e.g., cannabinoids, and optionally cannabidiol) in the formulation. Typical average molecular weights of polyethylene glycol groups can range from approximately 350 to approximately 7000 g / mol. In one application model, the average molecular weight of the polyethylene glycol group is approximately 1500. In another application model, the average molecular weight of the polyethylene glycol group is approximately 6000. In yet another application model, the average molecular weight of the polyethylene glycol group is approximately 400. In this applied model, cannabinoid formulations include one or more polyethylene glycol-containing fatty acid esters, usually a mixture of polyethylene glycol-containing fatty acid esters (mono- and di-polyethylene glycol fatty acid esters). Polyethylene glycol-containing fatty acid esters useful in formulations can be obtained from commercially available sources. Polyethylene glycol-containing fatty acid esters (mixtures of mono- and di-esters) are commercially available under the name GELUCIRE® (Gattefosse, Saint-Priest Cedex, France). Illustrative examples of suitable polyethylene glycol-containing fatty acid esters include GELUCIRE® 44 / 14, GELUCIRE® 48 / 16, GELUCIRE® 50 / 13, GELUCIRE® 59 / 14, and LabrasolALF. The numbers in these GELUCIRE® designations indicate the melting point and the hydrophilic / lipidic equilibrium (HLB) of the substance, respectively. In some application models, the polyethylene glycol-containing fatty acid esters in GELUCIRE® 44 / 14, GELUCIRE® 50 / 13, GELUCIRE® 59 / 14, or LabrasolALF consist of a mixture of (a) mono-, di-, and triglyceride esters (glycerides) and (b) mono-, di-, and triglyceride esters (macrogolates). In other application models, the polyethylene glycol-containing fatty acid esters in GELUCIRE® 44 / 14, GELUCIRE® 50 / 13, GELUCIRE® 59 / 14, or LabrasolALF consist of a mixture of (a) mono-, di-, and triglyceride esters and (b) mono- and di-esters of polyethylene glycol. In some applied models, polyethylene glycol is polyethylene glycol-32 (molecular weight 1500), polyethylene glycol-150 (molecular weight 6000), or polyethylene glycol-8 (molecular weight 400).In some application models, GELUCIRE® 44 / 14, GELUCIRE® 50 / 13, GELUCIRE® 59 / 14, or LabrasolALF are further composed of free polyethylene glycol (e.g., polyethylene glycol-32, polyethylene glycol-150, or polyethylene glycol-8). In some application models, the polyethylene glycol-containing fatty acid esters in GELUCIRE® 48 / 16 consist of a mixture of mono- and di-polyethylene glycol esters. In some application models, the polyethylene glycol is polyethylene glycol-32 (molecular weight 1500). In some application models, GELUCIRE® 48 / 16 also consists of free polyethylene glycol (e.g., polyethylene glycol-32). In some applied models, polyethylene glycol-containing fatty acid esters consist of one or more oleic acid esters, linoleic acid esters, lauric acid esters, palmitic acid esters, stearic acid esters, caprylic acid esters, or capric acid esters (i.e., mono- and di-polyethylene glycol lauric acid esters, mono- and di-polyethylene glycol palmitic acid esters, and mono- and di-polyethylene glycol stearic acid esters). Mixtures of these esters may also be used. In some applied models, lauric acid (C12) is the predominant fatty acid component in the glycerides and polyethylene glycol esters of GELUCIRE® 44 / 14. GELUCIRE® 44 / 14 is referred to as a mixture of glyceryl dilaurate (lauric acid distearate with glycerol) and polyethylene glycol dilaurate (lauric acid distearate with polyethylene glycol), and is commonly known as polyethylene glycol-32 glyceryl laurate (Gattefosse), lauroyl macrogol-32 glycerides EP, or lauroyl polyoxyl glycerides USP / NF. GELUCIRE® 44 / 14 is produced by reacting hydrogenated palm kernel oil with polyethylene glycol (average molecular weight 1500). In some applied models, GELUCIRE® 44 / 14 contains approximately 20% mono-, di-, and triglycerides, approximately 72% mono- and di-esters of polyethylene glycol 1500, and approximately 8% polyethylene glycol 1500. In some applied models, GELUCIRE® 44 / 14 consists of mono-, di-, and triglycerides of oleic acid (C18:1), with the mono-ester fraction being predominant. In some application formulations, GELUCIRE® 44 / 14 contains lauric acid esters (C12) (30 to 50%), myristic acid esters (C14) (5 to 25%), palmitic acid esters (C16) (4 to 25%), stearic acid esters (C18) (5 to 35%), caprylic acid esters (C8) (less than 15%), and capric acid esters (C10) (less than 12%). GELUCIRE® 44 / 14 may also contain free glycerol (typically less than about 1%) and <1 ppm ethylene oxide. In some application formulations, GELUCIRE® 48 / 16 is a polyethylene glycol monostearate (Type I) NF composed of polyethylene glycol-32 esters (molecular weight 1500) of palmitic acid (C16) and stearic acid (C18). In some application formulations, GELUCIRE® 48 / 16 is composed of polyethylene glycol-32 esters (molecular weight 1500) of palmitic acid (C16) and stearic acid (C18). In some application formulations, GELUCIRE® 50 / 13 is a polyoxyl / macrogol 32 NF / EP sterol glyceride composed of mono-, di-, and triglycerides and mono- and di-esters of palmitic acid (C16) and stearic acid (C18) in polyethylene glycol-32 (molecular weight 1500). In some application formulations, GELUCIRE® 50 / 13 is composed of mono-, di-, and triglycerides and mono- and di-esters of palmitic acid (C16) and stearic acid (C18) in polyethylene glycol-32 (molecular weight 1500). In some application models, GELUCIRE® 59 / 14 consists of a small fraction of mono-, di-, and triglycerides, primarily mono- and di-esters of lauric acid (C12) in polyethylene glycol-32 (molecular weight 1500) and polyethylene glycol-150 (molecular weight 6000). In some applied formulations, LabrasolALF consists of a small fraction of mono-, di-, and triglycerides, primarily caprylic (C8) and capric (C10) acid mono- and diesters in polyethylene glycol-8 (molecular weight 400). The functions of GELUCIRE® 44 / 14 include: (a) a solvent for poorly soluble compounds and a bioavailability enhancer; (b) a single-component formulation system: self-emulsifies in an aqueous liquid to a micro-emulsion – SMEDDS Type III; (c) a wetting agent; and (d) a lipid binder in melting processes. Safety for use is indicated by comprehensive toxicity assessments and prior use in approved pharmaceutical products. The functions of GELUCIRE® 48 / 16 include: (a) a solvent for compounds with a low LogP (lipid affinity index) and a bioavailability enhancer; (b) a single-component formulation system: self-emulsifies in an aqueous liquid to a micellar solution – SMEDDS Type IV; (c) use in melting (granulation, extrusion), granulation, and pressing processes; and (d) a wetting agent. The safety of use is indicated by the prior use in approved pharmaceutical products.The functions of GELUCIRE® 50 / 13 include: (a) a solvent for poorly soluble compounds and a bioavailability enhancer; (b) a single-excipient formulation system: self-emulsifies in an aqueous liquid to a coarse emulsion – SMEDDS Type III; (c) a drug release modifier; and (d) a lipid binder in melting processes. Safety for use is determined by toxicity data and prior use in approved pharmaceutical products. The functions of GELUCIRE® 59 / 14 include: (a) a solvent for poorly soluble compounds and a bioavailability enhancer; and (b) a single-excipient formulation system: self-emulsifies in an aqueous liquid to a fine emulsion – SMEDDS Type III. Safety for use is determined by comprehensive toxicity assessments and prior use in approved pharmaceutical products.LabrasolALF functions as follows: (a) a solvent for poorly soluble compounds and a bioavailability enhancer; (b) a single-excipient formulation system: it self-emulsifies in an aqueous liquid to a microemulsion – SMEDDS Type III; and (c) guaranteed high purity for stability and compatibility with capsules. Safety for use is indicated by comprehensive toxicity data and prior use in approved pharmaceutical products. Safety for use is also indicated by the food additive status and prior use in approved pharmaceutical products. In some application models, GELUCIRE® 44 / 14 has a melting range of 42.5 to 47.5 °C, an HLB equilibrium of 11, and a CMC of 72–53 mg / L at 25 °C. In some application models, GELUCIRE® 48 / 16 has a melting range of 46 to 50 °C, an HLB equilibrium of 12, and a CMC of 153–31 mg / L at 25 °C. In some application models, GELUCIRE® 50 / 13 has a melting range of 46 to 51 °C, an HLB equilibrium of 11, and a CMC of 100–31 mg / L at 25 °C. In some application models, GELUCIRE® 59 / 14 has a melting range of 57–62 °C, an HLB equilibrium of 14 × 1, and a CMC of 40 mg / L at 25 °C. In some application models, LabrasolALF has a viscosity of 80–110 mPa·s (20 °C), an HLB equilibrium of 12, and a CMC of 42 × 24 mg / L at 25 °C. Relative quantities of components in self-emulsifying drug delivery system formulations For applied models involving polyethylene glycol-containing fatty acid esters, in certain models, the ratio of glycerol fatty acid esters to polyethylene glycol-containing fatty acid esters ranges from approximately 30:70 to approximately 70:30 v / v. In one model, the ratio of glycerol fatty acid esters to polyethylene glycol-containing fatty acid esters is approximately 30:70 v / v. In another model, the ratio is approximately 40:60 v / v. In yet another model, the ratio is approximately 50:50 v / v. And in another model, the ratio is approximately 60:40 v / v.In one applied model, the ratio of glycerol esters of fatty acids to polyethylene glycol-containing fatty acid esters is approximately 70:30 v / v. In one application model, the cannabinoid composition reported in the disclosure includes cannabinoids (optionally cannabidiol), PECEOL®, and GELUCIRE® 44 / 14. In some application models, the PECEOL® to GELUCIRE® 44 / 14 ratio can range from 30:70 to 70:30 (e.g., 30:70, 40:60, 50:50, 60:40, and 70:30). In these application models, the PECEOL® to GELUCIRE® 44 / 14 ratio can range from 20:80 to 80:20 (e.g., 20:80 and 30:70), 40:60, 50:50, 60:40, 70:30, and 80:20. In one application model, the cannabinoid composition reported in the disclosure includes cannabinoids (optionally cannabidiol), PECEOL®, and GELUCIRE® 48 / 16. In these application models, the ratio of PECEOL® to GELUCIRE® 48 / 16 can range from 30:70 to 70:30 (e.g., 30:70, 40:60, 50:50, 60:40, and 70:30). In these application models, the ratio of PECEOL® to GELUCIRE® 48 / 16 can range from 20:80 to 80:20 (e.g., 20:80 and 30:70), 40:60, 50:50, 60:40, 70:30, and 80:20. In one application model, the cannabinoid composition reported in the disclosure includes cannabinoids (optionally cannabidiol), PECEOL®, and GELUCIRE® 50 / 13. In these application models, the ratio of PECEOL® to GELUCIRE® 50 / 13 can range from 30:70 to 70:30 (e.g., 30:70, 40:60, 50:50, 60:40, and 70:30). In these application models, the ratio of PECEOL® to GELUCIRE® 50 / 13 can range from 20:80 to 80:20 (e.g., 20:80 and 30:70), 40:60, 50:50, 60:40, 70:30, and 80:20. In one application model, the cannabinoid composition reported in the disclosure includes cannabinoids (optionally cannabidiol), PECEOL®, and GELUCIRE® 59 / 14. In these application models, the ratio of PECEOL® to GELUCIRE® 59 / 14 can range from 30:70 to 70:30 (e.g., 30:70, 40:60, 50:50, 60:40, and 70:30). In these application models, the ratio of PECEOL® to GELUCIRE® 59 / 14 can range from 20:80 to 80:20 (e.g., 20:80 and 30:70), 40:60, 50:50, 60:40, 70:30, and 80:20. In one application model, the cannabinoid composition reported in the disclosure includes cannabinoids (optionally cannabidiol), PECEOL®, and LabrasolALF. In these application models, the ratio of PECEOL® to LabrasolALF can range from 30:70 to 70:30 (e.g., 30:70; 40:60; and pan lang="ar-JO">50:50; 60:40; and 70:30). In these application models, the ratio of PECEOL® to LabrasolALF can range from 20:80 to 80:20 (for example, 20:80 and 30:70); 40:60; 50:50; 60:40; 70:30; and 80:20). In some applied models, glyceryl oleate and polyethylene glycol-containing fatty acid esters are present in the formulation at a percentage ranging from approximately 30% to approximately 50% by weight. In other applied models, both glyceryl oleate and polyethylene glycol-containing fatty acid esters are present in the formulation at percentages of approximately 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, and 50%. In some applied models, the fatty acid esters containing polyethylene glycol are Gelucire 44 / 14 or polyoxyl lauroyl glycerides. In some applied models, glyceryl oleate and polyethylene glycol-containing fatty acid esters are present in the composition at approximately 34.58% by weight. In other applied models, glyceryl oleate and polyethylene glycol-containing fatty acid esters are present at approximately 36.4% by weight. In yet other applied models, glyceryl oleate and polyethylene glycol-containing fatty acid esters are present at approximately 38% by weight. In some applied models, glyceryl oleate and polyethylene glycol-containing fatty acid esters are present at a composition ranging from approximately 39% to approximately 41% by weight. And in some applied models, glyceryl oleate and polyethylene glycol-containing fatty acid esters are present at approximately 40% by weight. In some applied models, the fatty acid esters containing polyethylene glycol are Gelucire 44 / 14 or polyoxyl lauroyl glycerides. The current report presents formulations of self-emulsifying cannabinoid drug delivery systems that may optionally include one or more additional components. These additional components may include one or more surfactants and auxiliary solvents. In some application models, the surfactant is tocopherol polyethylene glycol succinate (TPGS). In some application models, TPGS is present in the formulation at a concentration of approximately 3% to 4% by weight. In other application models, TPGS is present in the formulation at concentrations of approximately 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, or 4% by weight. In some applied models, polyethylene glycol tocopherol succinate is present in the formulation at approximately 3.64% by weight. In other applied models, polyethylene glycol tocopherol succinate is present in the formulation at approximately 4% by weight. In some application models, the co-solvent in the formulation is ethanol. In some application models, the ethanol content is approximately 7%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, or 8%. In some application models, the ethanol content is approximately 7.2% by weight. In other application models, the formulation does not contain ethanol. In some applied models, glyceryl oleate and polyethylene glycol-containing fatty acid esters comprise approximately 38% by weight, and polyethylene glycol tocopherol succinate comprises approximately 4% by weight. In other applied models, glyceryl oleate and polyethylene glycol-containing fatty acid esters comprise approximately 34.58% by weight, polyethylene glycol tocopherol succinate comprises approximately 3.64% by weight, and ethanol comprises approximately 7.2% by weight. In some application models, glyceryl oleate and polyethylene glycol-containing fatty acid esters are present in the formulation at approximately 36.4% by weight, and ethanol is present at approximately 7.2% by weight. In other application models, both glyceryl oleate and polyethylene glycol-containing fatty acid esters are present in the formulation at approximately 40% by weight, and the formulation does not contain polyethylene glycol tocopherol succinate or ethanol. In some clinical trials, a single dose of the formulation contains at least 10 milligrams (mg) of cannabinoids. In other clinical trials, a single dose of the formulation consists of approximately 10 mg to approximately 3,000 mg of cannabinoids. And in yet other clinical trials, a single dose of the formulation consists of approximately 50 mg to approximately 2,000 mg of cannabinoids. In some applied models, a single dose may consist of approximately 10 mg, or approximately 20 mg, or approximately 30 mg, or approximately 40 mg, or approximately 50 mg, or approximately 60 mg, or approximately 70 mg, or approximately 80 mg, or approximately 90 mg, or approximately 100 mg, or approximately 150 mg, or approximately 200 mg, or approximately 250 mg, or approximately 300 mg, or approximately 350 mg, or approximately 400 mg, or approximately 500 mg, or approximately 600 mg, or approximately 700 mg, or approximately 800 mg, or approximately 900 mg, or approximately 1,000 mg, or approximately 1,250 mg, or approximately 1,500 mg, or approximately 2,000 mg, or approximately 2,500 mg, or Approximately 3,000 mg of cannabinoids. In some applied models, a single dose consists of approximately 600 mg of cannabinoids. In some applied models, the current detection yields compounds containing cannabinoids greater than approximately 1% by weight. In some applied models, the compounds consist of approximately 10% to approximately 50% by weight. In some applied models, the compounds consist of approximately 20% by weight. In some applied models, the compounds consist of approximately 40% by weight. In some clinical trials, a single dose of the formulation contains at least 10 milligrams (mg) of CBD. In other clinical trials, a single dose of the formulation consists of approximately 10 mg to approximately 3,000 mg of CBD. And in yet other clinical trials, a single dose of the formulation consists of approximately 50 to 2,000 mg of CBD. In some applied models, a single dose may consist of approximately 10 mg, or approximately 20 mg, or approximately 30 mg, or approximately 40 mg, or approximately 50 mg, or approximately 60 mg, or approximately 70 mg, or approximately 80 mg, or approximately 90 mg, or approximately 100 mg, or approximately 150 mg, or approximately 200 mg, or approximately 250 mg, or approximately 300 mg, or approximately 350 mg, or approximately 400 mg, or approximately 500 mg, or approximately 600 mg, or approximately 700 mg, or approximately 800 mg, or approximately 900 mg, or approximately 1,000 mg, or approximately 1,250 mg, or approximately 1,500 mg, or approximately 2,000 mg, or approximately 2,500 mg, or Approximately 3,000 mg of CBD. In some applied models, a single dose consists of approximately 600 mg of CBD. In some applied models, the current discovery yields formulations containing CBD greater than approximately 5% by weight. In some applied models, the formulations consist of CBD at approximately 10% to approximately 50% by weight. In some applied models, the formulations contain CBD at approximately 20% by weight. In some applied models, the formulations contain CBD at approximately 40% by weight. The present disclosure also offers formulations, as described in this document, designed for oral administration. This disclosure includes a capsule containing any of the formulations described herein. In some application models, the capsule is a soft gelatin capsule. The cannabinoid self-emulsifying drug delivery system formulation can be formulated in any suitable form for delivering that formulation, such as, but not limited to, a capsule, tablet, powder, granules, or solution. cannabinoids Cannabinoids are naturally occurring and synthetic compounds structurally or pharmacologically related to components of the cannabis plant or to endogenous agonists (endocannabinoids) of the CB1 or CB2 cannabinoid receptors. Cannabinoids exert their physiological effects through a variety of receptors, including, but not limited to, adrenergic receptors, cannabinoid receptors (CB1 and CB2), GPR55, GPR3, and GPR5. The CB1 receptor is particularly prevalent in the central nervous system, with high levels in the neocortex, hippocampus, basal ganglia, cerebellum, and brainstem. Consequently, cannabidiol (CBD) has been proposed for the treatment of certain nervous system disorders (Scotteretal. Br. J. Pharmacol. 2010. (160):480-498). The main cannabinoids found in cannabis plants are tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), along with small amounts of their neutral (decarboxylated) cannabinoids. Additionally, cannabis may contain lower levels of other minor cannabinoids. Cannabidiol (CBD) is one of the main cannabinoid components in cannabis plants. Unlike other cannabinoids, such as tetrahydrocannabinol (THC), CBD does not bind to CB1 or CB2 receptors, or its binding to these receptors is minimal in terms of producing a pharmacological effect. Therefore, CBD does not produce central or peripheral nervous system effects mediated by CB1 or CB2 receptors. CBD has little or no psychoactive (cannabinoid-like) activity, and its molecular structure and properties differ significantly from those of other cannabinoids. In some applications, cannabidiol is isolated from the cannabis plant. In some applications, cannabidiol is synthesized. In some applications, cannabidiol exists as (-)-dissociated cannabidiol. Of the more than 100 naturally occurring cannabinoids identified in the cannabis plant, seven are classified as cannabidiol compounds. These cannabinoids share the same absolute structure as cannabidiol. They are: cannabidiol, cannabidiolic acid (CBDA), cannabidivarine (CBDV), cannabidivarine acid (CBDVA), cannabidiol-C1 (CBD-C1), cannabidiol-C4 (CBD-C4), and cannabidiol monomethyl ether (CBDM). Cannabidiolic acid (CBDA) is the primary form of cannabidiol found in the cannabis plant. It is converted to cannabidiol through decarboxylation. Cannabidiol-C1 (CBD-C1), also known as cannabidiocrol, is a homolog of cannabidiol, with its side chain shortened by four methylene bridges. CBD-C1 occurs naturally in plants that produce trace amounts of cannabidiol. Cannabidivarine (CBDV) is a cannabidiol analog, with its side chain shortened by two methylene bridges. CBDV is a non-psychoactive cannabinoid and has been shown to have anticonvulsant activity in a mouse model of epilepsy. Cannabidiol-C4 (CBD-C4), also known as nor-cannabidiol, is a homolog of cannabidiol, with its side chain shortened by one methylene bridge. CBD-C4 occurs naturally in plants that produce trace amounts of cannabidiol. Cannabidiol (CBD) is a highly lipophilic drug (logP ≈ 6) with low water solubility (estimated to be <13 µg / mL). Due to its intensive primary metabolism, CBD has an oral bioavailability of approximately 6%. Formally, CBD is classified as a Class II compound in the Biopharmaceutical Classification System (BCS) due to its low water solubility and high intestinal permeability. Therefore, strategies that can improve the dissolution or dispersion rate of CBD will increase its bioavailability. To this end, various formulation methods for CBD have been explored, including solid dispersions, nanocrystals, and nanoemulsions. Given CBD's physicochemical properties, lipid-based formulations have shown considerable success. To date, the only CBD formulation approved by the FDA is Epidiolex®, a sesame oil-based solution for the treatment of rare childhood epilepsy and tuberous sclerosis. However, this and other CBD formulations have limited application: (1) some patients are allergic to sesame oil, raising safety concerns; (2) many indications require higher doses of CBD that are difficult to administer with sesame oil formulations, creating compliance limitations; (3) liquid formulations are inherently less precise; and (4) sesame oil formulations degrade upon exposure to air, resulting in higher costs. Additionally, Epidiolex contains ethanol, which presents disadvantages for use in certain patient populations. Therefore, lipid-based formulations are needed that can improve CBD absorption without relying on sesame oil as an excipient, avoid potential allergies, allow for higher doses and improved patient compliance, reduce variability, and lower costs. CBD has been proposed as a treatment for a variety of conditions, including but not limited to, high-risk psychosis, insomnia, first psychotic episode, psychosis in Parkinson's disease, schizophrenia, generalized anxiety disorder, social anxiety disorder, panic disorder, post-traumatic stress disorder, Alzheimer's disease, postpartum psychosis, agoraphobia, acute stress disorder, and schizoaffective disorder. Treatment of some of these conditions may require high doses of CBD. Patient acceptance and adherence to treatment will be improved by a convenient and painless method of administration, preferably oral, using a soft gel that is easy to apply and highly effective. Therefore, CBD formulations with the following characteristics are needed: high CBD solubility and stability during storage, along with favorable safety, absorption, and bioavailability properties. Polyethylene glycol succinate D-α-tocopherol 1000 (TPGS) Cannabinoid formulations may optionally include one or more additional ingredients, including a surfactant such as D-alpha-tocopherol polyethylene glycol succinate (TPGS). Accordingly, in some applied models, the cannabinoid formulations mentioned in the disclosure include (a) cannabinoids, and cannabidiol may be optional; (b) one or more glycerol esters of fatty acids; (c) one or more fatty acid esters containing polyethylene glycol; and (d) polyethylene glycol tocopherol succinate, and optionally polyethylene glycol D-α-tocopherol 1000 (TPGS 1000). As used in this document, the term "D-α-tocopherol polyethylene glycol succinate" and the abbreviation "TPGS" are used interchangeably, and are defined as a molecule according to the chemical structure below: Polyethylene glycol tocopherol succinate is a bifacial molecule, prepared by esterifying a hydrophilic polyethylene glycol molecule (typically with an average molecular weight of 1000 and approximately 20–25 ethylene oxide chains) with the carboxyl group of the hydrophobic d-α-tocopherol hemisuccinate acid. Polyethylene glycol tocopherol succinate is a water-soluble compound (up to 20% w / v) and forms mesellitic solutions with a critical mesellitic concentration of 0.4–0.6 mmol / L (approximately 0.075%). The lipophilic-hydrophilic equilibrium of polyethylene glycol tocopherol succinate is approximately 15–19. Structurally, polyethylene glycol tocopherol succinate contains polyethylene glycol (PEG) covalently linked to a tocopherol (such as alpha-tocopherol or vitamin E) via a succinate linkage. Since polyethylene glycol is a polymer, a variety of polymer molecular weights can be used to prepare polyethylene glycol tocopherol succinate.In one application model, polyethylene glycol tocopherol succinate is TPGS 1000, where the average molecular weight of polyethylene glycol is 1000. One suitable polyethylene glycol tocopherol succinate is commercially available vitamin E polyethylene glycol tocopherol succinate from Eastman. Polyethylene glycol tocopherol succinate can also be used as a surfactant or emulsifier for lipophilic substances. Emulsification and the subsequent increase in the surface area of ​​the lipophilic substance may enhance gastrointestinal absorption and bioavailability of the drug. Adding polyethylene glycol tocopherol succinate to formulations can improve thermal stability, which may, in turn, extend the formulation's shelf life. In some application models, polyethylene glycol tocopherol succinate is present in the formulation at a concentration ranging from approximately 0.1% to approximately 10% by volume, depending on the total formulation volume. In one application model, polyethylene glycol tocopherol succinate is present in the formulation at approximately 5% by volume, depending on the total formulation volume. Toxicity studies have shown that polyethylene glycol tocopherol succinate is safe for human consumption as a food or dietary supplement. Furthermore, the antioxidant properties of polyethylene glycol tocopherol succinate may improve the stability of formulations containing it. Antioxidants Cannabinoid formulations may optionally contain one or more antioxidants. In some applied models, antioxidants are selected from a group consisting of polyethylene glycol tocopherol succinate, butylated hydroxytoluene (BHT), hydroxyanisole, alpha-tocopherol (vitamin E), ascorbyl palmitate, ascorbic acid, sodium ascorbate, ethylenediaminetetraacetic acid, cysteine ​​hydrochloride, citric acid, sodium citrate, sodium bisulfate, sodium metabisulfite, lecithin, propyl glycate, sodium sulfate, and monothioglycerol. In some applied models, one or more antioxidants consist of polyethylene glycol tocopherol succinate. In some applied models, one or more antioxidants consist of butylated hydroxytoluene. In some applied models, one or more antioxidants consist of polyethylene glycol tocopherol succinate and butylated hydroxytoluene. In some applied models, the cannabinoid structures described in this document consist of approximately 0.0.01% to about 20% by weight of antioxidant. In some applied models, the cannabinoid formulations described in this document contain antioxidants at approximately 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, or approximately 0.7%, or about 0.8%, or about 0.9%, or about 1%, or about 2%, or about 3%, or about 4%, or about 5%, or about 6%, or about 7%, or about 8%, or about 9%, or about 10%, or about 11%, or about 12%, or about 13%, or about 14%, or about 15%, or about 16%, or about 17%, or about 18%, or about 19%, or about 20% of the weight. ethanol Cannabinoid formulations may optionally include one or more additional ingredients, including an auxiliary solvent such as ethanol. Accordingly, in some applied models, the cannabinoid formulations mentioned in the disclosure include (a) a cannabinoid, which can be cannabidiol optionally; (b) one or more glycerol esters of fatty acids; (c) one or more esters of fatty acids containing polyethylene glycol; and (d) ethanol, optionally polyethylene glycol tocopherol succinate. Auxiliary solvents can enhance emulsification and influence the solubility of lipophilic compounds in simulated intestinal fluid. However, ethanol may also present a safety or patient preference concern. In some applied models, formulations do not contain ethanol. sesame oil The sesame oil-based formulation of Epidiolex® is FDA-approved for the treatment of rare childhood epilepsy and tuberous sclerosis. Sesame oil may increase the solubility and systemic exposure of cannabinoids. Furthermore, sesame oil facilitates enterohepatic transport of cannabidiol (CBD), effectively bypassing the first-pass effect and thus increasing bioavailability. However, considerable variability in absorption may be observed. Additionally, sesame oil may pose a safety concern for patients due to potential food allergies. In some clinical trials, formulations do not contain sesame oil. Medium chain triglyceride (MCT) oil Cannabinoid formulations, such as cannabidiol (CBD), may optionally include one or more additional components, including triglycerides, such as medium-chain triglyceride oil. Triglycerides (also known as triacylglycerol or triacylglycerol triglycerides) are glycerides in which glycerol is esterified with three fatty acids. Triglycerides can be divided into three categories based on their chain length: (i) short-chain triglycerides (SCTs); (ii) medium-chain triglycerides (MCTs); and (iii) long-chain triglycerides (LCTs). Medium-chain triglycerides contain fatty acids ranging from approximately C8 to approximately C10 (e.g., caprylic / capric triglycerides). Some examples of commercially available medium-chain triglycerides include CAPTEX® (available from Parchem, White Plains, NY), NESATOL® (available from Kreglinger Europe, Antwerp, Belgium), and WAGLINOL® (available from IndustrialQuimicaLasem, SA).Barcelona, ​​Spain), BERGABEST® (available from Sternchemie, Hamburg, Germany), MIGLYOL® (available from UniversalPreserv-A-Chem, Inc., Edison, New Jersey), NEOBEE® (available from StepanCompany, Northfield, Illinois), and CRODAMOL® (available from Croda, Edison, New Jersey). Methods for manufacturing self-emulsifying drug delivery systems The present report describes methods for manufacturing a self-emulsifying drug delivery system. In a self-emulsifying drug delivery system, the oily solution that self-emulsifies is called the preconcentrate. A large mixture of drug-free preconcentrate can be prepared by mixing the excipients at 45°C for approximately 30 minutes, stirring at a speed of about 300 rpm. The final concentrate can be prepared by adding the drug-free preconcentrate to the cannabinoid isolate until the cannabinoid concentration reaches the desired level. The mixture can then be stirred at a speed of about 400 rpm at about 45°C until it is completely homogeneous. Figure 1 illustrates an example of the manufacturing process for a cannabinoid self-emulsifying drug delivery system. Dispersion of the droplets The cannabinoid self-emulsifying drug delivery system formulations described include cannabinoids, and optionally cannabidiol, which are partially soluble (dissolved) and exist as solid particles to provide a fine solid dispersion. Dispersion of the formulations in aqueous media results in the formation of a fine nano-emulsion. The formulations can be distinguished by droplet size and the multiple dispersion index (PDI) measured by dynamic light scattering (DLS) (ZetasizerNanoZS, MalvernInstruments Ltd, UK) at approximately 37°C. Pre-concentrated materials can be dispersed in a phosphate-buffered saline solution (approximately 0.5% w / v). an>) and stir it rapidly at about 100 revolutions per minute and at about 37 degrees Celsius for approximately two hours. When dispersed, the composites may form submicron-sized droplets. In some applied models, the composites may form droplets with an initial diameter ranging from approximately 280 nm to approximately 500 nm. In other applied models, the composites may form droplets with an initial diameter ranging from approximately 380 nm to approximately 480 nm. In yet other applied models, the composites may form droplets with an initial diameter ranging from approximately 375 nm to approximately 490 nm. And in some applied models, the composites may form droplets with an initial diameter of approximately 429 nm. When dispersed, the structures may form droplets with multiple dispersion index values ​​ranging from approximately 0.2 to approximately 0.6. In some applied models, the structures may form droplets with multiple dispersion index values ​​ranging from approximately 0.25 to approximately 0.4. In some applied models, the structures may form droplets with multiple dispersion index values ​​ranging from approximately 0.2 to approximately 0.4. In some applied models, the structures may form droplets with multiple dispersion index values ​​of approximately 0.30. The formulations can be stored under refrigerated conditions (i.e., from approximately 3°C to approximately 5°C) or at room temperature (i.e., from approximately 20°C to approximately 25°C). They can be stored for a minimum of 3 months. Storage times can be approximately 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, 20 days, 30 days, 40 days, 50 days, 60 days, 70 days, 80 days, 90 days, or 100 days. After storage, the formulations may form droplets with the same diameter as those formed before storage. In some applied models, the formulations may form droplets with an initial diameter between approximately 280 nm and approximately 650 nm. In other applied models, they may form droplets with an initial diameter between approximately 380 nm and approximately 570 nm. In yet other applied models, they may form droplets with an initial diameter between approximately 380 nm and approximately 490 nm. Finally, in some applied models, they may form droplets with an initial diameter between approximately 429 nm and approximately 489 nm. In some applied models, the formulations, after storage under refrigerated conditions, may form droplets with an initial diameter ranging from approximately 400 nm to approximately 650 nm. In other applied models, after storage under refrigerated conditions, the formulations may form droplets with an initial diameter ranging from approximately 425 nm to approximately 580 nm. In some applied models, after storage at room temperature, the formulations may form droplets with an initial diameter ranging from approximately 400 nm to approximately 510 nm. In yet other applied models, after storage under refrigerated conditions, the formulations may form droplets with an initial diameter ranging from 420 nm to 490 nm. In some applied models, the formulations, after storage at room temperature, may form droplets with an initial diameter ranging from approximately 310 nm to approximately 560 nm. In other applied models, the formulations, after storage at room temperature, may form droplets with an initial diameter ranging from approximately 380 nm to approximately 520 nm. In yet other applied models, the formulations, after storage at room temperature, may form droplets with an initial diameter ranging from approximately 370 nm to approximately 430 nm. And in still other applied models, the formulations, after storage at room temperature, may form droplets with an initial diameter ranging from approximately 390 nm to approximately 410 nm. After storage, the formulations may form droplets with approximately the same multiple dispersion index (MDI) values ​​as those formed before storage. In some applied models, after storage, the formulations may form droplets with MDI values ​​ranging from approximately 0.05 to approximately 0.6. In other applied models, after storage, the formulations may form droplets with MDI values ​​ranging from approximately 0.14 to approximately 0.5. In some applied models, after storage under refrigerated conditions, the formulations may form droplets with MDI values ​​ranging from approximately 0.15 to approximately 0.45. In other applied models, after storage at room temperature, the formulations may form MDI values ​​ranging from approximately 0.2 to approximately 0.35. In some applied models, the formulations, after storage under refrigerated conditions, may form droplets with multiple dispersion index values ​​ranging from approximately 0.1 to approximately 0.6. In some applied models, the formulations, after storage under refrigerated conditions, may form droplets with multiple dispersion index values ​​ranging from approximately 0.14 to approximately 0.5. In some applied models, the formulations, after storage under refrigerated conditions, may form droplets with multiple dispersion index values ​​ranging from approximately 0.15 to approximately 0.45. In some applied models, the formulations, after storage at room temperature, may form droplets with multiple dispersion index values ​​ranging from approximately 0.15 to approximately 0.55. In some applied models, the formulations, after storage at room temperature, may form droplets with multiple dispersion index values ​​ranging from approximately 0.2 to approximately 0.5. In some applied models, the formulations, after storage at room temperature, may form droplets with multiple dispersion index values ​​ranging from approximately 0.15 to approximately 0.46. In some applied models, the formulations, after storage at room temperature, may form droplets with multiple dispersion index values ​​ranging from approximately 0.2 to approximately 0.35. Dissolving the medicine The cannabinoid-based self-emulsifying drug delivery systems (SEDS) that have been identified effectively dissolve the cannabinoid, with cannabidiol (CBD) optionally present, at a concentration of at least 1% by weight. In some application models, the formulations consist of cannabinoids (such as CBD) in amounts greater than or equal to approximately 5%, greater than or equal to approximately 10%, greater than or equal to approximately 15%, greater than or equal to approximately 20%, greater than or equal to approximately 25%, greater than or equal to approximately 30%, greater than or equal to approximately 35%, greater than or equal to approximately 40%, greater than or equal to approximately 45%, greater than or equal to approximately 50%, or greater than or equal to approximately 55% by weight. In some applied models, the formulations consist of cannabinoids in amounts ranging from approximately 1% to approximately 60% by weight, or from approximately 20% to approximately 50% by weight, or from approximately 30% to approximately 50% by weight, or from approximately 30% to approximately 40% by weight. In other applied models, the formulations consist of cannabinoids in amounts ranging from approximately 10% to approximately 50% by weight.In some applied models, the compounds consist of cannabinoids in a proportion ranging from approximately 20% to approximately 40% by weight. In some applied models, the compounds consist of cannabinoids in an amount of approximately 20% by weight. In some applied models, the compounds consist of cannabinoids in an amount of approximately 25% by weight. In some applied models, the compounds consist of cannabinoids in an amount of approximately 30% by weight. In some applied models, the compounds consist of cannabinoids in an amount of approximately 35% by weight. In some applied models, the compounds consist of cannabinoids in an amount of approximately 40% by weight. In some applied models, the compounds consist of cannabinoids in an amount of approximately 45% by weight. In some applied models, the compounds consist of cannabinoids in an amount of approximately 50% by weight. The formulations can be stored under refrigerated conditions (i.e., from about 3°C ​​to about 5°C) or at room temperature (i.e., from about 20°C to about 25°C). The stability of an auto-emulsified cannabinoid drug delivery system can be assessed at a predetermined time point, for example, by diluting the pre-concentrated material in ethanol (1:1000), vortexing for about 20 seconds, ultrasonic treatment in an ultrasonic bath (SonoswissAG, SW 3H, Switzerland) for about 5 minutes, and determining the cannabinoid quantity by high-performance liquid chromatography. After storage, for example under refrigerated conditions (i.e., approximately 3°C to 5°C) or at room temperature (i.e., approximately 20°C to 25°C), formulations may maintain cannabinoid solubility, measured as a percentage of cannabinoid content, at approximately the same level as the formulation before storage. In some application models, formulations after storage may contain a percentage of cannabinoid content (drug content) ranging from approximately 80% to approximately 110%. In other application models, formulations after storage may contain a percentage of cannabinoid content ranging from approximately 91% to approximately 104%. In some applied models, formulations, after being stored under refrigerated conditions, may contain a cannabinoid content ranging from approximately 94% to approximately 110%. In other applied models, formulations, after being stored under refrigerated conditions, may contain a cannabinoid content ranging from approximately 96% to approximately 104%. In some application samples, formulations stored at room temperature may contain between approximately 80% and 104% cannabinoids. In other applications, formulations stored at room temperature may contain between approximately 91% and 100% cannabinoids. And in yet other applications, formulations stored at room temperature may contain between approximately 91% and 95% cannabinoids. To determine their effectiveness as orally administered formulations, the stability of representative cannabinoid formulations of the invention was evaluated in a simulated gastric fluid. Drug dispersion and dissolution in simulated gastric fluid The cannabinoid self-emulsifying drug delivery system formulations described maintain favorable dispersion properties and effectively solubilize cannabinoids, including optional cannabidiol, in biologically relevant media (e.g., simulated gastric fluid including, but not limited to, simulated fasting gastric fluid [FaSSGF], simulated fasting intestinal fluid [FaSSIF], simulated feeding intestinal fluid [FeSSIF]. Fasting gastric fluid, fasting enteral fluid, and feeding enteral fluid are solubility media that mimic human intestinal fluid. Each contains the same types and levels of surfactants (bile salts and phospholipids) as the gastric fluid it mimics, along with the same average pH and osmolality. Surfactants, pH, and osmolality are important parameters to control when testing drugs or formulations. Surfactants form mixed micelles, which greatly improve drug solubility and dissolution. Both pH and osmolality also affect drug solubility and dissolution. Fasting gastric fluid consists of approximately 0.08 mM of taurocolate, approximately 0.02 mM of phospholipids, approximately 34 mM of sodium, and approximately 59 mM of chloride. The intestinal fluid mimicking the fasting state consists of approximately 3 millimolar of torochlorates, and approximately 0.The gastric fluid contains approximately 75 mM phospholipids, 148 mM sodium, 106 mM chloride, and 29 mM phosphates. The simulated feeding intestinal fluid contains approximately 15 mM tauric acid, 3.75 mM phospholipids, 319 mM sodium, 203 mM chloride, and 144 mM acetic acid. Powders and concentrates for the buffered solutions of the simulated fasting gastric fluid, simulated fasting intestinal fluid, and simulated feeding intestinal fluid were purchased from Biorelevant.com Ltd. In some applied models, after dispersion (0.5% w / v) in biologically relevant media, the formulations of the self-emulsifying cannabinoid drug delivery system described may contain approximately 90% to approximately 100% of the cannabinoids, including optional cannabidiol, dissolved within 30 minutes. In some applied models, dispersions of the formulations in gastric fluid simulated as fasting may contain at least 90% of the dissolved cannabinoids within 30 minutes for all formulations. In some applied models, dispersions of the formulations in gastric fluid simulated as fasting may contain at least 80% of the dissolved cannabinoids within 2 hours. In some applied models, dispersions of the formulations in gastric fluid simulated as fasting may contain at least 95% of the dissolved cannabinoids within 2 hours. In some applied models, the formulations dispersed in intestinal fluid simulating a fasting state may contain at least 90% dissolved cannabinoids within 30 minutes for all formulations.In some experimental models, the formulations dispersed in intestinal fluid simulating fasting conditions may contain at least 90% soluble cannabinoids within two hours. In some experimental models, the formulations dispersed in intestinal fluid simulating feeding conditions may contain at least 60% soluble cannabinoids within 30 minutes for all formulations. In some experimental models, the formulations dispersed in intestinal fluid simulating feeding conditions may contain at least 40% soluble cannabinoids within two hours. In vitro digestion of cannabinoid self-emulsifying drug delivery system formulations The solubility properties of the cannabinoid shown, for example, cannabidiol self-emulsifying drug delivery system formulations, can be further determined by in vitro digestion, for example, as described in (Koketal. Eur. J. Pharm. Sci. 2022, 168, 106058; or Williamsetal. J. Pharm. Sci. 2012, 101 (9), 3360–3380; or Sasseneetal. AAPSJ. 2014, 16 (6), 1344–1357). After dispersing (2.5% w / v) the selected formulations in the fasting-mimicking intestinal fluid by stirring at 100 rpm at 37°C for 10 minutes before adding pancreatic lipase (approximately 667 mg), and digesting for approximately 30 minutes, the samples can be separated by centrifugation (20,800 RPM, 15 minutes) into three layers: an upper layer (oil phase), a middle layer (mesellar aqueous phase), and a lower layer (precipitate phase). The cannabinoid content can be analyzed by high-performance liquid chromatography from each phase after dilution in methanol. In some applied models, the structures exhibit minimal precipitation (<20%) and are primarily distributed in the oil phase. In other applied models, the structures show a distribution of approximately 55% to 75% of the cannabinoids, e.g., cannabidiol (CBD), in the oil phase, approximately 18% to 28% in the aqueous phase, and approximately 7% to 21% in the granular phase. Still other applied models show a distribution of approximately 62% of the cannabinoids in the oil phase, approximately 23% in the aqueous phase, and approximately 15% in the granular phase. Pharmacokinetics The present findings present cannabinoid formulations, such as cannabidiol (CBD), which, after administration, may result in improved absorption and delayed excretion compared to the cannabinoid formulation of medium-chain triglyceride (MCT) oil, also referred to herein as cannabinoid MCT oil (optionally, CBD formulation of MCT oil, also referred to herein as CBD MCT oil). In some applied models, these formulations may, after administration, result in a peak plasma concentration (Cmax) approximately equal to, or at least as high as, or higher than the concentration achieved with oral MCT oil.In some applied models, the formulations, after administration, may result in a peak plasma concentration (Cmax) approximately equal to, or at least as high as, or higher than the concentration achieved by ingesting the cannabinoid formulation of sesame oil (SO), also referred to as cannabinoid sesame oil in this document (optionally, the cannabidiol formulation of sesame oil, also referred to as the sesame oil and cannabinoid formulation in this document). In some applied models, the formulations, after administration, may result in a peak concentration (Cmax) approximately 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, or 2.0 times greater than that of medium-chain triglyceride cannabinoid oil. In some applied models, the formulations, after administration, may lead to a maximum concentration (Cmax) approximately 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, or 2.0 times greater than the sesame oil concentration of cannabinoids.In some applied models, the formulations, after administration, may result in a peak concentration (Cmax) approximately 1.7 times greater than the concentration of medium-chain triglyceride oil of the cannabinoid. In other applied models, the formulations, after administration, may result in a peak concentration (Cmax) approximately 1.1 times greater than the concentration of medium-chain triglyceride oil of the cannabinoid. In some applied models, formulations may: (a) form droplets with a diameter within a specified range upon dispersion, and (b) induce, after administration, a maximum plasma concentration (Cmax) greater than a certain value. In some applied models, formulations may: (a) form droplets with a diameter between 280 nm and 500 nm upon dispersion, and (b) induce, after administration, a maximum plasma concentration (Cmax) greater than 500 ng / mL, greater than 550 ng / mL, greater than 600 ng / mL, greater than 650 ng / mL, greater than 700 ng / mL, or greater than 750 ng / mL. In some applied models, formulations may: (a) form droplets with a diameter between 380 nm and 480 nm as an initial diameter upon dispersion, and (b) induce, after administration, a maximum plasma concentration (Cmax) greater than 500 ng / mL, or greater than 550 ng / mL, or greater than 600 ng / mL, or greater than 650 ng / mL, or greater than 700 ng / mL, or greater than 750 ng / mL.In some applied models, the formulations may: (a) form droplets with a diameter between 375 nm and 490 nm as the initial diameter upon dispersion, and (b) induce, after administration, a maximum plasma concentration (Cmax) greater than 500 ng / mL, or greater than 550 ng / mL, or greater than 600 ng / mL, or greater than 650 ng / mL, or greater than 700 ng / mL, or greater than 750 ng / mL. In some applied models, the formulations may: (a) form droplets with an initial diameter of approximately 429 nm upon dispersion, and (b) induce, after administration, a maximum plasma concentration (Cmax) greater than 500 ng / mL, or greater than 550 ng / mL, or greater than 600 ng / mL, or greater than 650 ng / mL, or greater than 700 ng / mL, or greater than 750 ng / mL. In some applied models, the formulations may: (a) form, upon dispersion, droplets with an initial diameter of approximately 429 nm, and (b) induce, after administration, a maximum plasma concentration (Cmax) greater than 750 ng / mL. In some applied models, the formulations, after administration, may result in an area under the plasma concentration-time curve (AUC) from the time of administration (0 h) to the following 8 hours (AUC0–8 h) that is approximately equal to, at least as high as, or higher than that resulting from the administration of medium-chain triglyceride oil for cannabinoids. In some applied models, the formulations, after administration, may result in an AUC0–8 h that is approximately equal to, at least as high as, or higher than that resulting from the administration of sesame oil for cannabinoids. In some applied models, the formulations, after administration, may result in AUC0–8h values ​​approximately 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, or 2.0 times greater than the medium-chain triglyceride oil value for cannabinoids. In some applied models, the formulations, after administration, may result in AUC0–8h values ​​approximately 1.1 times, 1.2 times, 1.3 times, 1.4 times, or 1.5 times greater than the sesame oil value for cannabinoids.In some applied models, the formulations, after administration, may result in AUC0–8h values ​​approximately 1.9 times greater than that of medium-chain triglyceride oil for cannabinoids. In other applied models, the formulations, after administration, may result in AUC0–8h values ​​approximately 1.1 times greater than that of sesame oil for cannabinoids. In some clinical trials, the formulations, after administration, may have a time to reach peak concentration (Tmax) of approximately 30 minutes, 1 hour, 1.25 hours, 1.5 hours, 1.75 hours, or 2 hours. In some clinical trials, the formulations may have a Tmax time of approximately 1.75 hours. Individual dosage forms and administration The current formulations offer suitable formulations for delivering a wide range of cannabinoid doses, including cannabidiol (CBD) doses as an option. In some application models, the formulations allow for loading a larger quantity of the active cannabinoid substance, resulting in improved bioavailability and reduced pill or capsule size. Furthermore, the self-emulsifying drug delivery system formulations described in this document provide increased AUC concentrations compared to other formulations. These improved formulations enable more efficient and convenient administration of the cannabinoid product, particularly for conditions requiring a high therapeutic dose range. The formulations and standardized dosage forms allow for the administration of higher cannabinoid (e.g., CBD) doses compared to conventional formulations and standardized dosage forms, including, for example, doses greater than 1000 ng, doses from approximately 1000 mg to at least 3000 mg, and doses from approximately 1500 mg to approximately 2000 mg. In some applied models, a single dose of any of the formulations consists of approximately 10 mg to approximately 3,000 mg, or approximately 20 mg to approximately 2,000 mg, or approximately 30 mg to approximately 1,000 mg, or approximately 40 mg to approximately 800 mg, or approximately 50 mg to approximately 600 mg of cannabinoid, with the possibility of adding cannabidiol. In some applied models, a single dose of any of the formulations consists of approximately 100 mg to approximately 2,500 mg, or approximately 500 mg to approximately 2,500 mg, or approximately 1,000 mg to approximately 2,500 mg, or approximately 1,500 mg to approximately 2,500 mg, or approximately 500 mg to approximately 2,000 mg, or approximately 1,000 mg to approximately 2,000 mg, or approximately 1,500 mg to approximately 2,000 mg of a cannabinoid, for example, cannabidiol. In some applied models, a single dose (or standardized dosage form) may consist of approximately 50 mg to approximately 2,000 mg, or approximately 500 mg to approximately 2,000 mg, or approximately 1,000 mg to approximately 2,000 mg, or approximately 1,500 mg to approximately 2,000 mg, or 50 mg to approximately 1,000 mg, of cannabinoids, optionally cannabidiol.In some applied models, a single dose may consist of approximately 10 mg, or approximately 20 mg, or approximately 30 mg, or approximately 40 mg, or approximately 50 mg, or approximately 60 mg, or approximately 70 mg, or approximately 80 mg, or approximately 90 mg, or approximately 100 mg, or approximately 150 mg, or approximately 200 mg, or approximately 250 mg, or approximately 300 mg, or approximately 350 mg, or approximately 400 mg, or approximately 500 mg, or approximately 600 mg, or approximately 700 mg, or approximately 800 mg, or approximately 900 mg, or approximately 1,000 mg, or approximately 1,250 mg, or approximately 1,500 mg, or approximately 1,750 mg, or approximately 2,000 mg, or Approximately 2,500 mg, or approximately 3,000 mg, of cannabinoids, and optionally cannabidiol. In some clinical settings, one, two, or three doses may be administered daily. The disclosure presents standardized dosage forms of cannabinoid formulations. In some application models, the standardized dosage form is prepared for oral administration, for example, as a liquid, tablet, or capsule. In certain application models, the standardized dosage form consists of a therapeutically effective amount of the cannabinoid formulation, or two or more forms, for example, two, three, or four standardized dosage forms combined, each consisting of a therapeutically effective amount of the cannabinoid formulation. In some application models, each standardized dosage contains approximately 10 mg to approximately 3,000 mg, 20 mg to approximately 2,000 mg, 30 mg to approximately 1,000 mg, 40 mg to approximately 800 mg, or 50 mg to approximately 600 mg of cannabinoids, and optionally, cannabidiol (CBD).In some applied models, the standardized dosage form may consist of approximately 50 mg to approximately 2,000 mg, or approximately 500 mg to approximately 2,000 mg, or approximately 1,000 mg to approximately 2,000 mg, or approximately 1,500 mg to approximately 2,000 mg, or 50 mg to approximately 1,000 mg, of cannabinoids, and optionally cannabidiol. In some applied models, the standardized dosage form of any of the formulations consists of approximately 100 mg to approximately 2,500 mg, or approximately 500 mg to approximately 2,500 mg, or approximately 1,000 mg to approximately 2,500 mg, or approximately 1,500 mg to approximately 2,500 mg, or approximately 500 mg to approximately 2,000 mg, or approximately 1,000 mg to approximately 2,000 mg, or approximately 1,500 mg to approximately 2,000 mg of cannabinoid, for example, cannabidiol.In some applied models, the standardized dosage form may consist of approximately 10 mg, or approximately 20 mg, or approximately 30 mg, or approximately 40 mg, or approximately 50 mg, or approximately 60 mg, or approximately 70 mg, or approximately 80 mg, or approximately 90 mg, or approximately 100 mg, or approximately 150 mg, or approximately 200 mg, or approximately 250 mg, or approximately 300 mg, or approximately 350 mg, or approximately 400 mg, or approximately 500 mg, or approximately 600 mg, or approximately 700 mg, or approximately 800 mg, or approximately 900 mg, or approximately 1,000 mg, or approximately 1,250 mg, or approximately 1,500 mg, or approximately 1,750 mg, or approximately 2,000 mg; Or approximately 2,500 mg or 3,000 mg of cannabinoids, optionally cannabidiol. In some applied models, two or more standardized dosage forms, for example, two, three, or four forms, together constitute any of these total amounts of cannabinoids, for example, cannabidiol.In some applied models, the standardized dose consists of a range of cannabinoids, for example, cannabidiol, consisting of any two of the amounts described in this document, for example, from about 30 mg to about 300 mg. In some application models, the standardized dosage form of the aforementioned cannabinoid formulations contains at least 250 mg of a cannabinoid, such as CBD, with a total weight of less than 1500 mg. In certain application models, the standardized dosage form of the aforementioned cannabinoid formulations contains at least 300 mg of a cannabinoid, such as CBD, with a total weight of less than 1500 mg. In certain application models, the standardized dosage form of the aforementioned cannabinoid formulations contains at least 400 mg of a cannabinoid, such as CBD, with a total weight of less than 1700 mg. In certain application models, the standardized dosage form of the aforementioned cannabinoid formulations contains at least 500 mg of a cannabinoid, such as CBD, with a total weight of less than 2000 mg. In some application models, the current findings present cannabinoid formulations that can be administered orally, for example, in soft or hard gelatin capsules, and form relatively stable oil-in-water (O / W) emulsions, for example, upon aqueous dilution due to gentle stirring of gastrointestinal fluids. In some application models, the standardized dosage form is contained within a soft or hard gelatin capsule. In some application models, the detection is presented in a capsule, for example, a soft or hard gelatin capsule, containing the indicated cannabinoid composition consisting of at least 250 mg of a cannabinoid, such as CBD, with a total weight less than 1500 mg. In certain application models, a capsule containing the indicated cannabinoid composition consisting of at least 300 mg of a cannabinoid, such as CBD, with a total weight less than 1500 mg. In certain application models, a capsule containing the indicated cannabinoid composition consisting of at least 400 mg of a cannabinoid, such as CBD, with a total weight less than 1700 mg. In certain application models, a capsule containing the indicated cannabinoid composition consisting of at least 500 mg of a cannabinoid, such as CBD, with a total weight less than 2000 mg. In certain application models, a capsule containing a gelatinous cover or an outer gelatinous layer. The current findings present standardized formulations and dosage forms suitable for delivering a wide range of cannabinoid, and optionally cannabidiol, daily amounts. In some applied models, the cannabinoid formulation can be administered in amounts ranging from approximately 10 mg to approximately 3,000 mg of cannabinoid daily. In other applied models, the cannabinoid formulation can be administered in amounts ranging from approximately 50 mg to approximately 2,000 mg, or from approximately 50 mg to approximately 1,000 mg, of cannabinoid daily. In some applied models, the cannabinoid formulation may be given in amounts ranging from about 100 mg to about 2,500 mg, or from about 500 mg to about 2,500 mg, or from about 1,000 mg to about 2,500 mg, or from about 1,500 mg to about 2,500 mg, or from about 500 mg to about 2,000 mg, or from about 1,000 mg to about 2,000 mg, or from about 1,500 mg to about 2,000 mg of cannabinoid, for example, cannabidiol, daily.In some clinical trials, the cannabinoid formulation may be administered in doses of approximately 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1,000 mg, 1,250 mg, 1,500 mg, or 2,000 mg. 2,500 mg, or approximately 3,000 mg of cannabinoids daily. In some applied models, a combination of cannabinoid doses, for example, cannabidiol, consisting of any two of the amounts mentioned in this document, for example, from approximately 30 mg to approximately 300 mg. In some clinical trials where cannabinoid or CBD formulations are administered as a treatment for a clinically high-risk illness or injury in a participant, the cannabinoid formulation may be given in doses ranging from approximately 600 to approximately 1,000 mg daily. In some clinical trials where cannabinoid or CBD formulations are administered as a treatment for a clinically high-risk illness or injury in a participant, such as insomnia, the cannabinoid formulation may be given in doses ranging from 50 to 400 mg daily. In some clinical trials where cannabinoid or CBD formulations are administered as a treatment for a clinically high-risk illness or injury in a participant, such as generalized anxiety disorder, the cannabinoid formulation may be given in doses ranging from 300 to 600 mg daily.In some clinical trials where cannabinoid or CBD formulations are administered selectively to treat a participant's illness or injury, specifically panic disorder, the dosage may be 300–600 mg daily. In other clinical trials where CBD formulations are administered selectively to treat a participant's illness or injury, specifically post-traumatic stress disorder, the dosage may be 100–600 mg daily. And in yet other clinical trials where CBD formulations are administered selectively to treat a participant's illness or injury, specifically social anxiety disorder, the dosage may be 300–600 mg daily.In some applied models where a cannabinoid formulation, or cannabidiol formulation, is given electively as a method of treating an illness or injury in a study participant, where the illness or injury is the first psychotic episode, the cannabinoid formulation may be given in an amount of 600-1,000 mg daily. In some clinical trials where cannabinoid or CBD formulations are administered selectively as a treatment for a participant's illness or injury—specifically, psychosis in Parkinson's disease—the dosage may be 300–1,500 mg daily. In other clinical trials where cannabinoid or CBD formulations are administered selectively as a treatment for a participant's illness or injury—specifically, schizophrenia—the dosage may be 600–1,500 mg daily. The current findings present cannabinoid formulations that, after oral administration, may result in mesenteric lymph node cannabinoid concentrations higher than those in the liver. In some applied models, the formulations, after oral administration, may result in mesenteric lymph node cannabinoid concentrations approximately the same as those achieved with a sesame oil cannabinoid formulation. In some applied models, the formulations, after oral administration, may result in splenic cannabinoid concentrations lower than those in the mesenteric lymph node, brain, liver, or kidneys. In some applied models, the formulations, after oral administration, may result in mesenteric lymph node cannabinoid concentrations approximately 9 to 14 times higher than splenic cannabinoid concentrations. In some applied models, the formulations, after being administered orally, may result in a tissue distribution coefficient (Kp) for the mesenteric lymph node that is higher than the tissue distribution coefficient for the brain, liver, kidneys, or spleen. The effect of food on the pharmacokinetics of a cannabinoid self-emulsifying drug delivery system. The current report presents cannabinoid self-emulsifying drug delivery system formulations and optional cannabidiol self-emulsifying drug delivery system formulations that are, to a measurable degree, food-independent. Specifically, the formulations exhibit favorable pharmacokinetics when administered with food, within 2 hours, up to 4 hours, up to 8 hours or more after a meal, or after fasting for at least 2–12 hours. In some application models, the formulations are administered after fasting for at least 2 hours, or up to 4 hours, up to 6 hours, up to 8 hours, or up to 10 hours after a meal and / or up to at least 2 hours before a meal. In some application models, food is consumed only at least 2 hours after administration of the formulations. In some application models, food is consumed within approximately 2 hours before administration of the formulations. In some application models, the formulations are administered without food for at least 2 hours before and at least 2 hours after administration.In some case studies, formulations are administered on an empty stomach for at least 4 hours before and at least 4 hours after administration. In other case studies, the cannabinoid self-emulsifying drug delivery system formulations described, when administered at least 2 hours, 4 hours, 6 hours, 8 hours, or 10 hours after a meal, produce a peak cannabinoid concentration at least 50% of the peak concentration achieved when the formulation is administered orally at approximately the same time as a meal. In some applied models, formulations given at least 2 hours, or at least 4 hours, or at least 6 hours, or at least 8 hours, or at least 10 hours after eating, and at least 2 hours before eating, result in a cannabinoid AUC that is at least 50% of that following oral administration of the formulation at approximately the same time as eating. Methods of cannabinoid administration and treatment In some clinical trials, cannabinoid self-emulsifying drug delivery systems (DEDSs) and standardized dosage forms can be used to administer cannabinoids, including CBD, to the study participant. In some trials, the systems can be used to treat a disease or injury in a study participant who needs it, including administering or providing one or more DEDSs or standardized dosage forms to the participant. In some trials, the DEDS or standardized dosage forms are administered to the participant whether or not they are fasting. In some trials, the participant has eaten or is eating at approximately the same time they are given the DEDS or standardized dosage forms.In some clinical models, the study participant has eaten or is eating for at least 2 hours, 4 hours, 6 hours, 8 hours, or 10 hours before being given the cannabinoid self-emulsifying drug delivery system (DEDS) formulation or standardized dose form(s). In other clinical models, the study participant is given the DEDS formulation or standardized dose form approximately once a day, twice a day, or three times a day.In some applied models, the study participant is given a cannabinoid self-emulsifying drug delivery system formulation or standardized dose form(s) for at least one day or about one day, at least two days or about two days, at least three days or about three days, at least five days or about five days, at least one week or about one week, at least two weeks or about two weeks, at least one month or about one month, at least two months or about two months, at least four months or about four months, at least six months or about six months, at least one year or about one year, or for a longer period. In some applied models, the study participant is given cannabinoid, and optionally cannabidiol, orally in the form of three or fewer capsules (e.g., one or two capsules) containing a formulation disclosed in this document (e.g., a formulation of a self-emulsifying drug delivery system), and in some applied models, each capsule contains at least approximately 200 mg, or at least approximately 250 mg, or at least approximately 275 mg, or at least approximately 300 mg, or at least approximately 325 mg, or at least approximately 350 mg, or at least approximately 375 mg, or at least approximately 400 mg, or at least approximately 425 mg, or at least approximately 450 mg, or at least approximately 475 mg, or at least approximately 500 mg. In certain applied models, the study participant is given a total dose ranging from about 400 mg to about 1500 mg (or from about 600 mg to about 1000 mg) of cannabinoids, optionally cannabidiol, in three capsules or fewer. In some clinical trials, the study participant is given an oral dose of approximately 1000 mg, 200 mg, 3000 mg, 4000 mg, 5000 mg, or 6000 mg of a cannabinoid in a combination disclosed in this document (e.g., a self-emulsifying drug delivery system), for example, in one or more capsules. In other clinical trials, a combination of cannabinoid doses, for example, cannabidiol (CBD), consisting of any two of the amounts disclosed in this document, for example, from approximately 1000 mg to approximately 3000 mg, is administered. In some clinical trials, detection provides a method for treating a disease or injury in a study participant who needs it. This involves administering or providing a cannabinoid (e.g., cannabidiol) self-emulsifying drug delivery system formulation or one or more standardized dose forms to the study participant in a quantity sufficient to achieve a plasma AUC (e.g., AUC0-last or AUC0-inf) of at least 2000 ng / h / mL. In some clinical trials, the quantity sufficient to achieve a plasma AUC ranges from approximately 2000 ng / h / mL to approximately 3000 ng / h / mL. In other clinical trials, the quantity sufficient to achieve a plasma AUC ranges from approximately 2000 ng / h / mL to approximately 5000 ng / h / mL. In relevant applied models, the current finding provides a method for treating a disease or injury in a study participant, involving supplying the study participant with a cannabinoid, for example, cannabidiol, in a quantity and form sufficient to achieve an AUC of at least 2,000 ng.h. / ml, for example, between approximately 2,000 ng.h. / ml and approximately 4,000 ng.h. / ml, or between approximately 2,000 ng.h. / ml and approximately 3,000 ng.h. / ml, or between approximately 2,000 ng.h. / ml and approximately 5,000 ng.h. / ml. In the various treatment models described in this document, the illness or injury is selected from a group that includes high clinical risk conditions such as psychosis, insomnia, first psychotic episode, psychosis in Parkinson's disease, schizophrenia, generalized anxiety disorder, social anxiety disorder, panic disorder, post-traumatic stress disorder, Alzheimer's disease, postpartum psychosis, agoraphobia, acute stress disorder, and schizoaffective disorder. In some models, the illness or injury is high clinical risk of psychosis. In others, the illness or injury is insomnia. In the various applied models of treatment methods described in this document, the disease or injury is selected from a group that includes generalized epilepsy, post-traumatic epilepsy, severe depression, bipolar depression, postpartum depression, endometriosis, premenstrual dysphoric disorder, premenstrual dysphoric disorder, mood changes during menopause, sleep disturbances during menopause, cognitive changes during menopause, and obsessive-compulsive disorder. In some applied models, the disease or injury is selected from absence seizures, typical absence seizures, atypical absence seizures, atonic seizures, myoclonic seizures, infantile spasms (also known as West syndrome), juvenile myoclonic epilepsy, Lennox-Gastaut syndrome, progressive myoclonic epilepsy, tonic-clonic seizures, tonic-clonic seizures, myoclonic seizures, status epilepticus, focal loss of consciousness seizures, infancy myoclonic epilepsy, hereditary epilepsy with hypertrophic seizures, early infancy epileptic encephalopathy (also known as Ohtara syndrome), and myoclonic encephalopathy.Early childhood epilepsy, infantile focal migratory epilepsy, Dravet syndrome (also known as severe infancy myoclonic epilepsy), tuberous sclerosis complex, treatment-resistant epilepsy, childhood absence epilepsy, epilepsy with absence myoclonic seizures, epilepsy with blepharospasm (also called Jevons syndrome), epilepsy with tonic-clonic seizures (also called flaccid myoclonic epilepsy or Doss syndrome), developmental / epileptic encephalopathy with spinal wave activation during sleep (also called continuous spinal wave during sleep, electrical state of sleep epilepsy, or Landau-Kleffner syndrome), feverish infection-associated epilepsy syndrome (FIRES), hemiplegic-hemipolenic-epileptic seizures, juvenile absence epilepsy, juvenile myoclonic epilepsy, epilepsy with only generalized tonic-clonic seizures, Rasmussen syndrome, and types of epilepsy Progressive myoclonic epilepsy, Rett syndrome, CDKL5 deficiency disorder, benign Rolandic epilepsy, and intractable childhood epilepsy. In some applied models, the disease or injury is selected from Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.Treatment-resistant epilepsy, infantile spasms, CDKL5 deficiency disorder, Aicardi syndrome, Doss syndrome, Dup15 syndrome, SYNGAP1 epileptic encephalopathy, drug-resistant focal seizures, Sturge-Weber syndrome, epilepsy syndrome associated with febrile infection, focal epilepsy, developmental and epileptic encephalopathies, and myoclonic absence epilepsy. Examples Example 1: Lipid-based self-emulsifying oral formulations. Four cannabinoid self-emulsifying drug delivery system formulations (i.e., A, B, C, and D) (Figure 1) were developed, each containing 20% ​​w / w (total wt cannabidiol) (Table 1). A self-emulsifying drug delivery system is a homogeneous mixture of oils and / or surfactants and / or auxiliary solvents that spontaneously assemble into a colloidal dispersion or emulsion when mixed with an aqueous medium, such as in the gastrointestinal tract. The oily solution that self-emulsifies is called a pre-concentrate. A large mixture of drug-free preconcentrate was prepared by mixing the excipients at 45°C for 30 minutes, stirring at 300 rpm. The final preconcentrate was prepared by adding the drug-free preconcentrate to the CBD isolate to a concentration of 20% w / w CBD. This mixture was stirred at 400 rpm at 45°C until completely homogeneous. Each formulation contains a 50:50 (w / w) ratio of picol to glycerol 44 / 14. The formulations differed in the presence or absence of an additional surfactant (tocopherol polyethylene glycol succinate) or co-solvent (anhydrous ethanol). Table 1: Summary of the formulations of the preparations. Cannabidiol (% w / w) Excipients (% w / w) Picol Glycer 44 / 14 Polyethylene Glycol Succinate Tocopherol Ethanol Cannabidiol A20 38 38 4 Self-Emulsifying Drug Delivery System — Cannabidiol "B" Auto-Emulsifying Drug Delivery System 20 34.58 34.58 3.64 7.2 Cannabidiol C 20 40 40 Self-Emulsifying Drug Delivery System — — Cannabidiol "D" self-emulsifying drug delivery system 20 36.4 36.4 — 7.2 In addition, the sesame oil formulation (sesame oil and cannabinoids) was prepared based on previous reports (Kok, LY; Banigan, P.; Sanae, F.; Evans, JC; Dunne, M.; Regenold, M.; Ahmed, L.; Dubins, D.; and Allen, C. Development and Pharmacokinetic Evaluation of a Self-Nanoemulsifying Drug Delivery System for the Oral Delivery of Cannabidiol. Eur. J. Pharm. Sci. 2022, 168, 106058. https: / / doi.org / 10.1016 / j.ejps.2021.106058). In summary, the final formulation consists of sucralose (0.05% w / w), strawberry flavoring (0.02% w / w), anhydrous ethanol (7.91% w / w), sesame oil (82.02% w / w), and cannabidiol (CBD) (10% w / w). Sucralose and strawberry flavoring were dissolved in anhydrous ethanol and mixed using a vortex mixer for 20 seconds. Sesame oil was added gravimetrically, and the solution was stirred at 250 rpm for 30 minutes. The sesame oil solution was then added to the CBD to a concentration of 10% w / w and stirred under the same conditions until completely homogeneous.The sesame oil and cannabinoid combination oil was stored away from direct light at room temperature until later use. A caprylic / capric triglyceride formulation (cannabidiol medium-chain triglyceride oil) was prepared by adding oil to cannabidiol to a concentration of 10% w / w. The medium-chain triglyceride oil solution was stirred at 250 rpm until completely homogeneous and stored away from direct light at room temperature until further use. Example 2: Properties and stability of cannabinoid self-emulsifying drug delivery system formulations The formulations of the cannabidiol self-emulsifying drug delivery system were characterized by droplet size and the multi-dispersion index (PDI) measured by dynamic light scattering (DLS) (ZetasizerNanoZS, MalvernInstruments Ltd, UK) at 37°C. The pre-concentrated material was dispersed in phosphate-buffered saline (0.5% w / v) and stirred at 100 rpm at 37°C for 2 hours. Upon mixing with the phosphate-buffered saline, the cannabidiol self-emulsifying drug delivery system produced clear, milky dispersions with no visible signs of drug precipitation. The resulting droplets were smaller than a micron, with initial diameter and multiple dispersion index values ​​of approximately 400 nm and 0.40, 480 nm and 0.37, 430 nm and 0.30, and 460 nm and 0.25, for the cannabidiol self-emulsifying drug delivery system “A”, “B”, “C”, and “D”, respectively (Table 2). Table 2: Summary of physicochemical properties and stability data for the self-emulsifying cannabidiol drug delivery system A, B, C, and D (mean ± standard deviation). Preconcentrated materials (n = 3) were stored in the absence of light, under refrigerated (i.e., 3–5°C) and room temperature (i.e., 20–25°C) conditions for one month. T0 Two weeks One month 4 degrees Celsius 25 degrees Celsius 4 degrees Celsius 25 degrees Celsius Cannabidiol A self-emulsifying drug delivery system Drug content (%) 92.8 ± 4.6 103.2 ± 3.1 95.3 ± 3.4 98.0 ± 3.2 99.4 ± 4.1 Drug dissolution rate within one hour (%) 97.6 ± 6.8 96.8 ± 12.9 91.8 ± 2.8 96.2 ± 3.5 94.5 ± 11.8 Diameter (nanometers) 389 ± 103 573 ± 74 347 ± 21 457 ± 26 380 ± 64 Multiple scattering index 0.40 ± 0.12 0.50 ± 0.10 0.39 ± 0.09 0.39 ± 0.09 0.41 ± 0.13 Self-emulsifying drug delivery system for cannabidiol "b" Drug content (%) 98.2 ± 3.0 97.4 ± 2.9 95.8 ± 1.7 97.9 ± 2.0 95.2 ± 1.0 Drug dissolution rate within one hour (%) 99.4 ± 5.6 95.2 ± 11.6 98.6 ± 4.0 93.2 ± 8.7 105.0 ± 2.1 Diameter (nanometers) 477 ± 35 502 ± 42 509 ± 48 571 ± 45 512 ± 26 Multiple scattering index 0.37 ± 0.07 0.41 ± 0.05 0.41 ± 0.16 0.37 ± 0.07 0.50 ± 0.07 Self-emulsifying drug delivery system for cannabidiol "C" Drug content (%) 93.0 ± 1.7 103.4 ± 6.5 95.0 ± 0.7 96.4 ± 1.4 91.6 ± 10.4 Drug dissolution rate within one hour (%) 98.1 ± 6.7 94.5 ± 3.4 106.0 ± 3.2 98.1 ± 2.3 96.3 ± 2.1 Diameter (nanometers) 429 ± 59 489 ± 20 392 ± 20 429 ± 30 403 ± 22 Multiple scattering index 0.30 ± 0.10 0.45 ± 0.11 0.20 ± 0.05 0.15 ± 0.04 0.34 ± 0.12 Self-emulsifying drug delivery system for cannabidiol "D" Drug content (%) 94.6 ± 0.8 95.0 ± 0.7 95.6 ± 1.0 97.0 ± 1.0 96.1 ± 1.3 Drug dissolution rate within one hour (%) 97.1 ± 11.4 99.0 ± 7.8 89.5 ± 2.2 97.7 ± 2.2 100.5 ± 5.4 Diameter (nanometers) 458 ± 23 443 ± 19 477 ± 48 487 ± 44 422 ± 22 Multiple scattering index 0.25 ± 0.07 0.18 ± 0.07 0.29 ± 0.05 0.14 ± 0.06 0.25 ± 0.04 The size of the dispersion droplets appears to be directly related to the drug loading level across the four formulations, with the empty formulations exhibiting approximately half the radius of the formulations tested (Figure 2). The oil formulations (e.g., sesame oil and cannabinoid, medium-chain triglyceride oil of cannabidiol) were not evaluated for dispersibility as they did not appear to disperse. The dissolution of formulations with varying CBD content was evaluated after dispersion (0.5% w / v) for 1 hour at 37°C in phosphate-buffered saline for a series of primary filtered dispersions (Figure 3A) and selected unfiltered dispersions (Figure 3B). Formulations 1, 2, 3, and 4 correspond to CBD self-emulsifying drug delivery systems A, B, C, and D, respectively. Formulations 1 and 3 in Figure 3B correspond to CBD self-emulsifying drug delivery systems A and C, respectively, when loaded with 20% w / w CBD. Formula 2 in Figure 2B consists of Picol:Glucer 44 / 14:Tocopherol polyethylene glycol succinate at a ratio of 45.6%:30.4%:4% w / w, and formula 4 in Figure 3B consists of Picol:Glucer 50 / 13 at a ratio of 48%:32% w / w. None of the dispersed samples showed significant drug precipitation.It was found that filtering the dispersants increased the variability of drug dissolution measurements, but the average dissolution was consistent with unfiltered dispersants. The stability of the cannabidiol self-emulsifying drug delivery system formulations, with respect to their dispersion patterns, was evaluated under refrigerated and room temperature conditions. Storage of the pre-concentrated materials under either refrigerated or room temperature conditions did not result in a significant change in droplet diameter or optical dispersion index over one month (Table 2). The dispersion properties of cannabidiol self-emulsifying drug delivery systems A, B, C, and D were maintained stably after storage under either room temperature or refrigerated conditions for one month (Figure 4). The dispersion patterns of all four formulations were found to be stable after storage at room temperature for three months (Figure 5). The CBD content in the pre-concentrated materials remained stable at room temperature for three months (Figure 6). Although all formulations maintained CBD concentrations within 10% of the initial measurement, a general decrease in variability was observed for formulations containing ethanol (CBD Auto-Emulsifying Drug Delivery System B and D) compared to those without the co-solvent (CBD Auto-Emulsifying Drug Delivery System A and C). The chemical stability of CBD in the Auto-Emulsifying Drug Delivery System formulations was similar to that of the sesame oil (SO) formulation (Figure 7). Example 3: Dispersion of self-emulsifying cannabinoid drug delivery system formulations in simulated gastric fluid The dispersion of cannabidiol self-emulsifying drug delivery system formulations was evaluated in biologically relevant media: fasting-mimicking gastric fluid (FaSSGF), fasting-mimicking intestinal fluid (FaSSIF), and feeding-mimicking intestinal fluid (FeSSIF), compared to phosphate-buffered saline (PBS). FaSSGF, FaSSIF, and FeSSIF are dissolution media that mimic human intestinal fluid. Each contains the same types and levels of surfactants (bile salts and phospholipids) as the gastroenteric fluid it mimics, along with the same mean pH and similar osmolality. Surfactants, pH, and osmolality are important parameters to control when testing drugs or formulations. Surfactants form mixed micelles, which significantly improves drug solubility and dissolution. Both pH and osmolality affect drug solubility and dissolution. Gastric fluid mimicking fasting conditions consists of approximately 0.The intestinal fluid simulating fasting consists of approximately 0.8 mM of taurocholate, 0.02 mM of phospholipids, 34 mM of sodium, and 59 mM of chloride. The intestinal fluid simulating feeding consists of approximately 3 mM of taurocholate, 0.75 mM of phospholipids, 148 mM of sodium, 106 mM of chloride, and 29 mM of phosphates. The intestinal fluid simulating feeding consists of approximately 15 mM of taurocholate, 3.75 mM of phospholipids, 319 mM of sodium, 203 mM of chloride, and 144 mM of acetic acid. Powders and concentrates for the buffer solution of gastric fluid simulating fasting, enteric fluid simulating fasting, and enteric fluid simulating feeding were purchased from Biorelevant.comLtd. The cannabidiol self-emulsifying drug delivery system (0.5% w / v) was dispersed in biologically relevant media (fasting-mimicking intestinal fluid, fasting-mimicking gastric fluid, or feeding-mimicking intestinal fluid) and stirred at 100 rpm and 37°C. At minutes 5, 30, 60, and 120, 800 µL of the dispersion fractions were removed, and the medium was replenished. The dispersion fractions were diluted in methanol prior to high-performance liquid chromatography (HPLC). All biologically relevant media were prepared according to the supplier's instructions, using concentrated buffer solutions. The differential effects of the media on the amount of CBD dissolved over 2 hours were observed (Figure 8). Overall, the dispersion patterns of all formulations in the fasting-mimicking gastric fluid were similar to those in phosphate-buffered saline, with over 90% CBD dissolved throughout the study. For the fasting-mimicking gastric fluid dispersants, at least 90% CBD was dissolved within 30 minutes for all formulations. Starting at 1 hour, the percentage of dissolved CBD decreased in all fasting-mimicking gastric fluid dispersions but remained above 80% throughout the study. In contrast, the dispersion patterns in the feeding-mimicking gastric fluid showed a significantly lower amount of dissolved CBD compared to the dispersion of other biologically relevant media. The dispersions of the self-emulsifying cannabidiol “A” and “C” drug delivery system in intestinal fluid mimicking the feeding condition were the most different, based on Fréchet distance, from any other formulations dispersed in any other media (Figure 9A).Furthermore, the dispersions of cannabidiol a and c self-emulsifying drug delivery systems in the simulated feeding intestinal fluid differed significantly in terms of the area under the dispersion pattern (AUC) compared to the same formulations dispersed in the simulated fasting intestinal fluid (Figure 9B). These dispersions showed signs of aggregation, which was more pronounced during the later time phases of the study. The dispersions of cannabidiol b and d self-emulsifying drug delivery systems in the simulated feeding intestinal fluid did not show the same signs of aggregation. Example 4: In vitro digestion of cannabinoid self-emulsifying drug delivery system formulations The distribution of cannabidiol after in vitro digestion for 30 minutes was assessed for the self-emulsifying drug delivery system of cannabidiol “C” and “D” (Figure 10). In brief, a 2.5% w / v cannabidiol self-emulsifying drug delivery system was prepared in 40 mL of fasting intestinal fluid. The medium was stirred at 100 rpm and 37°C throughout the study. Stirring continued for 10 minutes, after which pancreatic lipase (667 mg) was added to initiate digestion. After 30 minutes of digestion, 800 µL of the medium was separated by centrifugation (20,800 RPM, 15 min) into three layers: an upper layer (oil phase), a middle layer (mesellar aqueous phase), and a lower layer (settled precipitate phase). The cannabidiol content of each phase was analyzed by high-performance liquid chromatography after dilution in methanol. For the C-type self-emulsifying drug delivery system, CBD was distributed at 62 ± 6%, 23 ± 5%, and 15 ± 6% in the oily, aqueous, and granular phases, respectively. For the D-type self-emulsifying drug delivery system, the amount of CBD recovered from the oily, aqueous, and granular phases was 72 ± 2%, 19 ± 1%, and 9 ± 2%, respectively. Overall, both formulations exhibited minimal precipitation. Neither formulation was found to contain a granular phase in the control samples after initial dispersion at 10 minutes (i.e., prior to digestion). Prior to the addition of pancreatic lipase, the aqueous phase of the cannabidiol C auto-emulsifying drug delivery system contained a significantly higher percentage of cannabidiol compared to the cannabidiol D auto-emulsifying drug delivery system (p < 0.01), by 47 ± 4% and 24 ± 1% respectively. Example 5: Pharmacokinetic parameters of cannabinoid formulations in vivo The pharmacokinetics of the self-emulsifying drug delivery system for cannabidiol “C” and “D” were evaluated and compared to those of medium-chain triglyceride oil and sesame oil for cannabidiol after oral administration to mice at a dose of 20 mg / kg (Figure 11). For pharmacokinetic studies, rats were administered cannabidiol medium-chain triglyceride oil (CBDMCT), cannabidiol sesame oil carrier (CBDSO), or one of two self-emulsifying drug delivery systems (CEP-C or CEP-D) via oral force-feeding at a dose of 20 mg / kg of cannabidiol (n = 5 per formulation). Self-emulsifying drug delivery system formulations were freshly prepared 30 minutes prior to each experiment by pre-diluting the pre-concentrated material in deionized water (1:20 w / v) followed by vortex mixing for 20 seconds. Blood samples (200 μL) were collected via the collateral saphenous vein at 0.25, 0.5, 1, 2, 4, and 6 hours (with time points of 1.5 and 3 hours). Mice were given a medium-chain triglyceride (MCT) oil complex after being placed in heparin-containing tubes. Eight hours after administration, the mice were sacrificed by cardiac puncture and blood collection, followed by decapitation. Blood samples collected during the study were centrifuged (1000 RPM, 10 minutes, 4°C; 15 minutes for the final sample) to obtain plasma, which was transferred to microcentrifuge tubes and stored at -80°C pending further analysis. A second group of mice was administered a sesame oil-cannabinoid formulation, a cannabidiol C-emulsified drug delivery system, and a cannabidiol D-emulsified drug delivery system (n = 5 per formulation group) in a follow-up study of pharmacokinetics and tissue distribution to concentrate over the timescale around the predicted peak plasma concentration. In this study, blood samples were collected and stored in the same manner as before at 0.5, 1, 1.5, 2, and 3 hours, with the final blood collection occurring 4 hours after formulation administration. Plasma fractions (50 µL) were added to microcentrifuge tubes containing 2 µL of internal standard (THC; 100 µg / mL in methanol) pre-dried under a nitrogen evaporator (Glas-ColZipVap, Terre Haute, Indiana, USA). Each tube was filled with 450 µL of acetonitrile:ethyl acetate (50:50 v / v), mixed using a vortex mixer for 10 minutes, and centrifuged (15,300 RPM, 10 minutes, 4°C). The supernatant (400 µL) was transferred to an autosample flask and dried under nitrogen at 37°C. The samples were then reconstituted in 150 microliters of methanol, mixed using a vortex mixer, and centrifuged again under the same conditions, before being transferred to autosampler vias for subsequent analysis via high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS). Plasma concentration-time curves showed similar performance among the sesame oil-cannabinoid formulations and the CBD-C and CBD-D self-emulsifying drug delivery systems, with significantly higher absorption and slower clearance for each of these formulations compared to CBD medium-chain triglyceride oil (Figure 12). Table 3 summarizes the corresponding pharmacokinetic parameters. No statistically significant differences were obtained between the sesame oil-cannabinoid formulation, CBD medium-chain triglyceride oil, or any of the self-emulsifying drug delivery system formulations. Table 3: Pharmacokinetic parameters. Data are shown as mean ± SEM, number ≥ 5. Tmax is shown as mean and range. The formula Cmax (ng / ml) Tmax (hr) [range] AUC0–4 h (hr × ng / ml) AUC0–8 h (hr × ng / ml) AUC0–∞ (hr × ng / ml) t1 / 2 (hr) kel (h–1) AUC0–last / AUC0–∞ Cannabidiol medium-chain triglyceride oil 449 ± 61 1.5 [1–2] 967 ± 142 1198 ± 168 1328 ± 159 2.7 ± 0.8 0.31 ± 0.05 0.89 ± 0.03 Sesame oil and cannabinoids 688 ± 146 1 [0.25–2] 1615 ± 419 2146 ± 671 2634 ± 766 2.9 ± 1.3 0.45 ± 0.07 0.80 ± 0.05 Cannabidiol C self-emulsifying drug delivery system 768 ± 95 1.75 [0.5–2] 1926 ± 226 2291 ± 310 3133 ± 338 3.2 ± 0.9 0.37 ± 0.08 0.73 ± 0.05 Cannabidiol "d" Autoemulsifying Drug Delivery System 784 ± 198 1 [0.5–2] 1741 ± 301 2087 ± 388 3405 ± 762 3.9 ± 1.5 0.32 ± 0.06 0.72 ± 0.07 Although not statistically significant, the Cmax concentration and systemic exposure to CBD from the sesame oil cannabinoid formulation and the CBD C and D auto-emulsifying drug delivery systems were slightly higher than those from medium-chain triglyceride (MCT) oil. The Cmax values ​​for the sesame oil cannabinoid formulation and the CBD C and D auto-emulsifying drug delivery systems were 1.5, 1.7, and 1.8 times greater, respectively, than those of MCT oil. In terms of AUC0–8 h, the values ​​for the sesame oil cannabinoid formulation and the CBD C and D auto-emulsifying drug delivery systems were 1.8, 1.9, and 1.7 times greater than those of MCT oil, respectively. The average Tmax for the sesame oil and cannabinoid formulation and the cannabidiol “D” auto-emulsifying drug delivery system was 1 hour, while it was 1.75 hours for the cannabidiol “C” auto-emulsifying drug delivery system and 1.Five hours for CBD medium-chain triglyceride oil (MCT) (Figures 13A–13D). The Cmax and AUC values ​​for CBDA C and D auto-emulsified drug delivery systems were slightly higher than those of the sesame oil and cannabinoid combination. Within 8 hours of oral administration, the observed total exposure was approximately 73% for CBDA C and 72% for CBDA D. In contrast, the sesame oil and cannabinoid combination and CBD MCT oil achieved 80% and 89% of their total exposure, respectively, during the same period. Notably, a decrease in variability was observed for CBDA C and CBD MCT oil (Figures 14 and 15). Example 6: Tissue distribution after oral administration of cannabinoid self-emulsifying drug delivery system formulations The distribution of cannabidiol in the brain, liver, kidney, spleen, and mesenteric lymph node was assessed 4 hours after oral administration to the second group of mice described in Example 5 of 20 mg / kg cannabidiol in a sesame oil-cannabinoid combination or a cannabidiol “C” auto-emulsifying drug delivery system or a cannabidiol “D” auto-emulsifying drug delivery system (Figure 16). Tissues (i.e., brain, liver, kidney, spleen, and mesenteric lymph node (MLN)) were collected as quickly as possible after blood drainage, rinsed with phosphate-buffered saline, and rapidly frozen on dry ice. The tissues were stored at -80°C pending further analysis. Tissue samples (approximately 100–250 mg) were weighed into glass vials and homogenized with phosphate-buffered saline (1:4 w / v; 1:6 w / v for mesenteric lymph node) at 12,000 rpm for 5 minutes (Polytron®PT 2500 E, KinematicaAG, Lucerne, Switzerland). The homogenate (150 µL; 30 µL per mesenteric lymph node) was transferred to a small centrifuge tube containing 2 µL of internal standard (THC; 100 µg / ml in methanol) pre-dried under nitrogen, and 1.35 ml (270 µL per mesenteric lymph node) of acetonitrile:ethyl acetate (50:50 v / v) was added.The mixture was vortexed for 10 minutes and placed in an ultrasonic bath for 10 minutes at room temperature before centrifugation (15,300 RPM, 10 minutes, 4°C). The supernatant (1.4 mL; 250 µL for mesenteric lymph node) was transferred to an autosample flask and dried under nitrogen at 37°C. The samples were then reconstituted in 150 µL of methanol, vortexed, and centrifuged again under the same conditions before being transferred to autosample flasks for subsequent HPLC-MS / MS analysis. For all formulations, the highest CBD concentrations were found in the mesenteric lymph nodes, which were approximately twice the levels found in the liver. The sesame oil and cannabinoid formulation resulted in a significantly higher CBD concentration in the mesenteric lymph node compared to the CBDA D auto-emulsifier (p < 0.05), but not the CBDA C auto-emulsifier. The lowest CBD concentrations were found in the spleen for all formulations. Compared to the spleen CBD concentration, mesenteric lymph node concentrations were 11.4-fold higher for the sesame oil and cannabinoid formulation, 13.2-fold higher for the CBDA C auto-emulsifier, and 9.5-fold higher for the CBDA D auto-emulsifier. Tissue partitioning coefficients were calculated as the ratio of cannabidiol concentration in each tissue to the corresponding plasma concentration at 4 hours (Table 4). The tissue partitioning coefficient was highest for the mesenteric lymph node for each formulation. These results confirm that lymphatic uptake of cannabinoids plays a significant role in their absorption following oral administration in lipid-based formulations containing LCT. Furthermore, they confirm that the use of sesame oil as a delivery medium is not necessary to achieve the desired absorption effects with self-emulsifying drug delivery system formulations. Table 4. Summary of tissue partitioning coefficients. Data are presented as mean ± SEM, n = 5. The distribution coefficient (Kp) values ​​were calculated as the ratio between the cannabidiol concentration in each tissue and the corresponding plasma concentration at 4 hours. The composition is the tissue distribution coefficient (Kp). Brain, liver, kidneys, spleen, mesenteric lymph node Sesame oil and cannabinoids 29.2 ± 3.0 148.1 ± 78.8 30.0 ± 2.9 16.7 ± 2.3 305.4 ± 151.2 Cannabidiol C self-emulsifying drug delivery system: 11.6 ± 2.0, 45.0 ± 7.9, 15.7 ± 3.4, 7.0 ± 0.9, 94.2 ± 8.4 Cannabidiol "d" self-emulsifying drug delivery system 16.7 ± 1.8 37.4 ± 3.0 26.7 ± 7.2 9.7 ± 2.2 92.8 ± 19.5 Example 7: Pharmacokinetic parameters of cannabinoid self-emulsifying drug delivery system formulations in fasting animals The pharmacokinetics of the cannabidiol C (CBC) self-emulsifying drug delivery system were evaluated in fasted and non-fasting Sprague-Dawley rats following oral administration of 20 mg / kg (Figure 17, Figure 18). Time-course plasma concentration curves reveal that plasma CBD levels peak at a higher rate in non-fasting animals compared to fasting animals. Table 5 summarizes the corresponding pharmacokinetic parameters. Cmax and systemic CBD exposure were approximately 1.5-fold and 1.75-fold higher, respectively, in non-fasting animals compared to fasting animals. AUC0–8 h values ​​were approximately 1.6-fold higher in non-fasting animals, and the mean Tmax was 1.75 h in non-fasting animals, compared to 1 h in fasting animals. Within 8 hours of oral administration, the observed total exposure was approximately 73% in non-fasting animals and 92% in fasting animals. Table 5. Pharmacokinetic parameters. Data are shown as mean ± SEM (number ≥ 5). Tmax is shown as mean and range. Fasting Cmax (ng / ml) Tmax (hr) [Range] AUC0–4 h (hr × ng / ml) AUC0–8 h (hr × ng / ml) AUC0–∞ (hr × ng / ml) kel (h–1) AUC0–last / AUC0–∞ No. 768 ± 95 1.75 [0.5–2] 1926 ± 226 2291 ± 310 3133 ± 338 0.37 ± 0.08 0.73 ± 0.05 Yes 521 ± 86 1 [0.5–1.5] 1192 ± 232 1450 ± 292 1566 ± 305 0.35 ± 0.03 0.92 ± 0.01 Example 8: Pharmacokinetic parameters of cannabinoid formulations in vivo The increased bioavailability of the cannabidiol self-emulsifying drug delivery system formulation was examined compared to other cannabidiol formulations. The pharmacokinetics of the cannabidiol self-emulsifying drug delivery system formulation (encapsulated micelle cannabidiol (EMCBD)) were evaluated and compared to those of the active pharmaceutical ingredient of cannabidiol (CBDAPI) and the sesame oil (SO) formulation after oral administration to fed or fasted mice at a dose of 20 mg / kg according to the study design shown in Figure 19. For groups 1 and 4 (the pharmaceutically active ingredient of cannabidiol), a 121.8 mg sample of cannabidiol isolate was combined with an appropriate amount of solvent consisting of 40% cyclic hydroxypropyl betadextrin. For groups 2 and 5 (encapsulated micellar cannabidiol), a self-emulsifying drug delivery system (PDC) formulation was prepared by adding 1 g each of picol and glycerol to a vial and heating to 45°C for 30 minutes with stirring at 300 rpm. The final PDC was prepared by adding 1.00 g of the drug-free PDC to 0.470 g of the cannabidiol isolate, resulting in a 32% w / w concentration. This mixture was stirred at 400 rpm at 45°C until completely homogeneous. The formulation of the self-emulsifying drug delivery system was then freshly prepared prior to dosing, by pre-diluting the pre-concentrated materials in 30 ml of deionized water (1:80 w / v, e.g., 0.25 g of the preconcentrate (32% w / w) was dissolved in 20 mL of water, followed by vortex mixing for 20 seconds. For groups 3 and 6 (sesame oil and cannabinoid formulations), approximately 0.005 g of sucralose and 0.002 g of strawberry flavoring were dissolved in 1 mL of anhydrous ethanol and mixed using a vortex mixer for approximately 20 seconds. Approximately 8.92 mL of sesame oil was added, and the product was stirred at 250 rpm for 30 minutes. The sesame oil mixture was then added to 0.330 g of CBD isolate to a concentration of 10% w / w and stirred under the same conditions until completely homogeneous. The concentrations of CBD extract in the dosing solutions were determined by LC-MS / MS. Female Sprague-Dawley rats, aged 52–61 days, were administered a 20 mg / kg dose of cannabidiol (CBD) (n = 8 per formulation group). Blood was collected 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose via jugular vein. Plasma samples were obtained by centrifugation and frozen until plasma CBD concentrations were determined by LC-MS / MS. The plasma concentration of the CBD isolate in the rats was subjected to non-parametric pharmacokinetic analysis using PhoenixWinNonlin software (version 8.3, CertaraUSA, Inc.). Nominal times were used for the pharmacokinetic parameters. Peak plasma concentrations (Cmax) and corresponding peak times (Tmax) were determined directly from plasma concentration-time curves. Individual plasma concentration values ​​for orally administered animals that were below the minimum measurable quantity (LLOQ) before Tmax were set to zero, and those following Tmax were excluded from the calculation of pharmacokinetic parameters.The terminal half-life (T1 / 2), the area under the plasma concentration-time curve (AUC) from time zero to the last measurable concentration (AUC0-last) and from time zero to infinity (AUC0-inf), and the mean residence time (MRT) from time zero to the last measurable concentration (MRT0-last) and from time zero to infinity (MRT0-inf) were calculated using the descending logarithmic linear ascending rule. All plasma concentrations and pharmacokinetic parameters are reported as at least three significant figures. A one-way ANOVA model with food processing as the constant and the transformed analyte value as the dependent variable was used to estimate the effect of food processing on Cmax and AUC0-last. The mean values ​​of the major pharmacokinetic parameters are summarized in Figure 20. Figures 21-25 provide graphical representations of the mean values ​​of the major pharmacokinetic parameters obtained from fed or fasting animals after administration of various cannabidiol formulations. Based on Cmax and AUC0-last, the bioavailability of cannabidiol (CBD) was higher with the emulsified drug delivery system (EMCBD) formulation compared to the cyclic hydroxypropyl betadextrin formulation (CBD's active pharmaceutical ingredient) after administration on an empty stomach, and was even higher after administration with food (Figures 21 and 24). The AUC0-last concentration of CBD was also higher with the EMCBD formulation compared to the sesame oil formulation (CBD WO) after administration on an empty stomach, and was even higher after administration with food (Figure 24). The peak drug concentration (Cmax) was lower with the EMCBD formulation than with the sesame oil formulation after administration on an empty stomach, while it was higher with the EMCBD formulation than with the sesame oil formulation after administration with food (Figure 21).The bioavailability of cannabidiol (CBD) was increased by food intake of the self-emulsifying drug delivery system (SDDS) formulation, whereas the slight effect of food on the cyclic hydroxypropyl betadextrin (CHDDS) and sesame oil formulations was not significant for the observed pharmacokinetic variability between animals. These results demonstrate superior bioavailability for CBD SDDS formulations, enhanced by food intake. All publications, U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, and foreign patent applications mentioned in this document and / or listed in the application data sheet are included herein for the purpose of disclosing and describing the methods and / or materials cited in the publications. It is understood that this disclosure supersedes any disclosure in an incorporated publication in the event of a conflict. As is evident from the foregoing, although specific application models of the invention are described in this document for illustrative purposes, various modifications can be made without deviating from the spirit and scope of what is stated in the scope of the invention. Therefore, the invention is unlimited. Reference to drawings Figure 1 a-cannabidiol b) Partition factor logP c) Solubility in water D-Drug e-Surface-tension reducer and the auxiliary solvent Z-Oil h-Pre-concentrated material T- Gently stirring in the aqueous medium Y-Emulsion K-Self-emulsifying drug delivery system Figure 2 a-Diameter (nanometers) b-Composition C-Cannabidiol (% w / w) Figure 3A A- Dissolving the drug (%) b-Composition C-Cannabidiol (% w / w) Figure 3b A- Dissolving the drug (%) Figure 4 A- Self-emulsifying drug delivery system for cannabidiol "A" b- Self-emulsifying drug delivery system for cannabidiol "b" C-Self-emulsifying drug delivery system for cannabidiol "C" D-A self-emulsifying drug delivery system for cannabidiol "D" e-Drug dissolution (%) - Time (in minutes) g-day (storage temperature) Figure 5 A- Self-emulsifying drug delivery system for cannabidiol "A" b- Self-emulsifying drug delivery system for cannabidiol "b" C-Self-emulsifying drug delivery system for cannabidiol "C" D-A self-emulsifying drug delivery system for cannabidiol "D" e-Drug dissolution (%) - Time (in minutes) Z-Today Figure 6 A- Drug content (%) b-Composition C- Self-emulsifying drug delivery system for cannabidiol "A" D-Self-emulsifying drug delivery system for cannabidiol "b" e-Self-emulsifying drug delivery system for cannabidiol "C" and - a self-emulsifying drug delivery system for cannabidiol "D" Z-Today Figure 7 A- Drug content (%) b-Composition C- Sesame oil and cannabinoids D-Self-emulsifying drug delivery system for cannabidiol "C" e- Self-emulsifying drug delivery system for cannabidiol "d" And today Figure 8 A- Dissolving the drug (%) b) Self-emulsifying drug delivery system for cannabidiol "A" C- Self-emulsifying drug delivery system for cannabidiol "b" D-Self-emulsifying drug delivery system for cannabidiol "C" e- Self-emulsifying drug delivery system for cannabidiol "d" And amidst the distraction g- Gastric fluid mimicking fasting conditions H-Intestinal fluid mimicking the fasting state Intestinal fluid mimicking the feeding state Y-Phosphate-regulated saline solution K-Time (in minutes) Figure 9a A-Frish distance Figure 9b a- The area under the measured curve b-Amidst the dispersion c) Gastric fluid mimicking the fasting state D-Intestinal fluid mimicking the fasting state E-Intestinal fluid mimicking the feeding state and - phosphate-regulated saline solution Figure 10 a-Cannabidiol (%) B-Oil C-Aquatic Dr. Al-Habibi E-Composition F - Self-emulsifying drug delivery system for cannabidiol "C" g-Self-emulsifying drug delivery system for cannabidiol "d" h-Time (in minutes) Figure 11 A-Hour: b) Forced oral feeding c) Blood sample d-Collecting and analyzing blood samples lateral saphenous vein Figure 12 a-Plasma concentration (ng / ml) b) Time (in hours) c-Composition d-Cannabidiol medium-chain triglyceride oil E-Sesame oil and cannabinoids F - Self-emulsifying drug delivery system for cannabidiol "C" g-Self-emulsifying drug delivery system for cannabidiol "d" Figure 13A A-Tmax (hour) b- Medium-chain triglyceride oil C- Sesame oil D- Self-emulsifying drug delivery system "C" E- Self-emulsifying drug delivery system “D” Figure 13b A-Cmax (ng / ml) b- Medium-chain triglyceride oil C- Sesame oil D- Self-emulsifying drug delivery system "C" E- Self-emulsifying drug delivery system “D” Figure 13c A-AUC0-8 h (hour × ng / ml) b- Medium-chain triglyceride oil C- Sesame oil D- Self-emulsifying drug delivery system "C" E- Self-emulsifying drug delivery system “D” Figure 13d A-AUC0-∞ (hour × ng / ml) b- Medium-chain triglyceride oil C- Sesame oil D- Self-emulsifying drug delivery system "C" E- Self-emulsifying drug delivery system “D” Figure 14 a-Plasma concentration (ng / ml) b-Cannabidiol medium-chain triglyceride oil C- Sesame oil and cannabinoids D-Self-emulsifying drug delivery system for cannabidiol "C" e- Self-emulsifying drug delivery system for cannabidiol "d" And - time (in hours) Figure 15 a-Plasma concentration (ng / ml) b-Cannabidiol medium-chain triglyceride oil C- Sesame oil and cannabinoids D-Self-emulsifying drug delivery system for cannabidiol "C" e- Self-emulsifying drug delivery system for cannabidiol "d" And - time (in hours) Figure 16 a- Cannabidiol concentration (ng / g) b-The brain c-Liver Kidneys E-Textile and the spleen g-Mesenteric lymph node H-Composition Sesame oil and cannabinoids E-Self-emulsifying drug delivery system for cannabidiol "C" K-Self-emulsifying drug delivery system for cannabidiol "D" Figure 17 a-Plasma concentration (ng / ml) b) Time (in hours) C-Fasting ="ar-SA">d-la Yes Figure 18 a-Plasma concentration (ng / ml) b) Time (in hours) C-Fasting D-No Yes Figure 19 A- Study Design b-The group (method) C- Nutritional status d-Animal ID E-Treatment and - sample collection Test material H-Dosage (mg / kg) Dosage size (ml / kg) Y-Concentration (mg / ml) K-Carrier material L-Time points after the dose (in hours) M-1 (oral) N-2 (oral) Q-3 (oral) C-4 (oral) F-5 (oral) Page 6 (orally) Q-It was fed R-Fasting (overnight, with food reintroduced two hours after taking the dose) C-Cannabidiol isolating agent T-40% of cyclic hydroxypropyl betadextrin in water* Th-Carrier material for self-emulsifying drug delivery system # x-Carrier material for sesame oil ## 40% of cyclic hydroxypropyl betadextrin in water* The carrier material for the self-emulsifying drug delivery system # A. The carrier material for sesame oil. BB-0.5, 1, 2, 3, 4, 8, and 24 hours C-API: Pharmaceutical active ingredient, CBD: Cannabidiol, F: Female, PO: Oral, SEDDS: Self-emulsifying drug delivery systems. DD-* HPBCD: 2-hydroxypropyl beta-cyclodextrin H-# Carrier material for self-emulsifying drug delivery system: Cannabidiol active pharmaceutical ingredient - 32% w / w; PeceolTM - 34% w / w; Gelucire® 44 / 14 - 34% w / w. and -## Carrier of Sesame Oil: Pharmaceutical active ingredient cannabidiol - 10% w / w; Sucralose - 0.05% w / w; Ethyl 3-methyl-3-phenyl glycides (strawberry flavor) - 0.02% w / w; Anhydrous ethanol - 7.91% w / w; Sesame oil - 82.02% w / w. Figure 20 A-Cannabidiol isolating agent b) Analysis material C-Groups D-Teachers e-Cmax (ng / ml) W-Tmax (hour) Z-T1 / 2 (hour) H-AUC0-Iast (ng.h / ml) T-AUC0-inf (ng.h / ml) Y-MRT0-last (hour) K-MRT0-inf (clock) Figure 21 A-Fasting b) It was fed C-State Group d-Cannabidiol mecellarily coated E-Sesame oil and cannabinoids The active pharmaceutical ingredient of cannabidiol Z-Analysis Value H- Pharmacokinetic parameter = Cmax (ng / ml) Figure 22 A- Pharmacokinetic parameter = Tmax (ng / ml) b-Analysis value C- The active pharmaceutical component of cannabidiol d-Sesame oil and cannabinoids E-encapsulated micelle cannabidiol W-State Group It was fed H-Fasting Figure 23 a- Pharmacokinetic parameter = T1 / 2 (hour) b-Analysis value C- The active pharmaceutical component of cannabidiol d-Sesame oil and cannabinoids E-encapsulated micelle cannabidiol W-State Group It was fed H-Fasting Figure 24 A- Pharmacokinetic parameter = AUClast (ng.h / ml) b-Analysis value C- The active pharmaceutical component of cannabidiol d-Sesame oil and cannabinoids E-encapsulated micelle cannabidiol W-State Group It was fed H-Fasting Figure 25 A- Pharmacokinetic parameter = AUCinf (ng.h / ml) b-Analysis value C- The active pharmaceutical component of cannabidiol d-Sesame oil and cannabinoids E-encapsulated micelle cannabidiol W-State Group It was fed H-Fasting

Claims

1. A cannabinoid formulation consisting of: a cannabinoid; one or more glycerol esters of fatty acids; and one or more polyethylene glycol-containing fatty acid esters.

2. A formulation according to Protection Element 1, where the cannabinoid is cannabidiol.

3. A formulation according to Protection Element 1, where the cannabinoid is present in the formulation in an amount greater than 5% by weight.

4. A formulation according to Protection Element 1, where the cannabinoid is present in the formulation in an amount between 10% and 50% by weight.

5. A formulation according to Protection Element 1, where the cannabinoid is present in the formulation in an amount of 20% by weight.

6. A formulation according to Protection Element 1, where the cannabinoid is present in the formulation in an amount of 40% by weight. 7- The composition according to protection element 1, where glycerol esters of fatty acids and polyethylene glycol-containing fatty acid esters form a ratio in the range of 30:70 to 70:

30. 8- The composition according to protection element 1, where one or more of the glycerol esters of fatty acids are composed of glyceryl oleate (bisol).

9. Formulated according to protection factor 1, where one or more polyethylene glycol-containing fatty acid esters consist of one or more of the following: polyoxyl lauroyl glycerides (Gelucere 44 / 14), GELUCIRE® 48 / 16, GELUCIRE® 50 / 13, GELUCIRE® 59 / 14, and Laprasol ALF.

10. Formulated according to protection factor 7, where glycerol esters of fatty acids and polyethylene glycol-containing fatty acid esters are present in the formula at a percentage ranging from 30% to 60% by weight.

11. Formulated according to protection factor 10, where glycerol esters of fatty acids and polyethylene glycol-containing fatty acid esters are present in the formula at a percentage ranging from 39% to 41% by weight. 12- The formula conforms to protection factor 11, containing glycerol esters of fatty acids and polyethylene glycol-containing fatty acid esters at a rate of 40% by weight. 13- The formula conforms to protection factor 10, containing glycerol esters of fatty acids and polyethylene glycol-containing fatty acid esters at a rate of 36%.4% by weight, where ethanol is present in the formulation at 7.2% by weight. 14- The formulation according to protection element 10, where D-α-tocopheryl 1000 polyethylene glycol succinate (TPGS) is present in the formulation at an amount ranging from 3% to 4% by weight. 15- The formulation according to protection element 14, where glycerol esters of fatty acids and polyethylene glycol-containing fatty acid esters are present in the formulation at 38% by weight, and where TPGS is present in the formulation at 4% by weight. 16- The formulation according to protection element 14, where glycerol esters of fatty acids and polyethylene glycol-containing fatty acid esters are present in the formulation at 34.58% by weight, where TPGS is present in the formulation at 3.64% by weight, and where ethanol is present in the formulation at 7.2% by weight. 17- Formulated according to protective element 9, where the fatty acid esters containing polyethylene glycol consist of polyoxyl glycerides of lauroyl (Glycer 44 / 14). 18- Formulated according to protective element 1, where the formula contains one or more antioxidants.

19. Formula according to Protection Element 18, where one or more antioxidants are composed of butylhydroxytoluene (BHT).

20. Formula according to Protection Element 1, where a single dose of the formula contains at least 50 mg of cannabinoids.

21. Formula according to Protection Element 20, where a single dose of the formula contains 50 to 2,000 mg of cannabinoids.

22. Formula according to Protection Element 21, where a single dose consists of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1,000 mg, 1,250 mg, or 1,500 mg of cannabinoids.

23. Formulated according to protection factor 22, where a single dose contains 100 mg of cannabinoids.

24. Formulated according to protection factor 22, where a single dose contains 300 mg of cannabinoids.

25. Formulated according to protection factor 22, where a single dose contains 600 mg of cannabinoids.

26. The formulation according to protection factor 22, where a single dose consists of 1,000 mg of cannabinoids.

27. The formulation according to protection factor 1, where the formulation is administered to treat a disease or injury in a study participant, with the formulation given in amounts ranging from 50 to 3,000 mg of cannabinoids daily.

28. The formulation, according to protection element 27, is administered as part of a treatment regimen for an illness or injury in the study participant, at a dosage of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1,000 mg, 1,250 mg, 1,500 mg, 2,000 mg, 2,500 mg, or 3,000 mg of cannabinoids daily.

29. The formulation, according to protection element 28, is administered as part of a treatment regimen for an illness or injury in the study participant, at a dosage of 100 mg of cannabinoids daily.

30. The formulation, according to Protection Element 28, is administered as part of a treatment regimen for a disease or injury in a study participant, with a daily dose of 300 mg of cannabinoids.

31. The formulation, according to Protection Element 28, is administered as part of a treatment regimen for a disease or injury in a study participant, with a daily dose of 600 mg of cannabinoids.

32. The formulation, according to Protection Element 28, is administered as part of a treatment regimen for a disease or injury in a study participant, with a daily dose of 1,000 mg of cannabinoids.

33. The formulation, according to Protection Element 1, is designed for oral administration.

34. The formulation, according to Protection Element 1, is a self-emulsifying drug delivery system.

35. The formulation, according to Protection Element 1, does not contain sesame oil or ethanol. 36- The formulation is in accordance with protection element 1, whereby the concentration of cannabinoids is maintained at a quantity greater than 80% of the initial concentration, after storage at room temperature for up to three months.

37. The formulation meets Protection Factor 1, where the peak cannabinoid concentration after oral administration of the formulation is at least equal to the peak cannabinoid concentration after oral administration of the sesame oil and cannabinoid formulation.

38. The formulation meets Protection Factor 1, where the systemic exposure (AUC₥) to cannabinoids after oral administration of the formulation is at least equivalent to that after oral administration of the sesame oil and cannabinoid formulation.

39. The formulation meets Protection Factor 1, where the peak cannabinoid concentration after oral administration of the formulation is at least 2 hours, or at least 4 hours, or at least 6 hours, or at least 8 hours, or at least 10 hours after a meal, and at least 2 hours before a meal, is at least 50% of the concentration after oral administration of the formulation at approximately the same time as the meal.

40. Formula according to Protection Element 1, where the systemic exposure (AUC₥) to the cannabinoid after oral administration of the formula is at least 2 hours, or at least 4 hours, or at least 6 hours, or at least 8 hours, or at least 10 hours after a meal, and at least 2 hours before a meal, at least 50% of the concentration after oral administration of the formula at approximately the same time as a meal.

41. Formula containing more than 5% by weight of cannabinoids.

42. Formula according to Protection Element 41, consisting of 10% to 50% by weight of cannabinoids.

43. Formula according to Protection Element 42, consisting of 20% by weight of cannabinoids.

44. Formula according to Protection Element 42, consisting of 40% by weight of cannabinoids. 45- A capsule containing a formula according to protection element 1. 46- The capsule according to protection element 45, where the capsule is a soft gel capsule.

47. A method for administering cannabinoids to a study participant, consisting of administering a formulation according to protection factor 1 or a capsule according to protection factor 45 or protection factor 46.

48. A method for treating an illness or injury in a study participant who requires it, consisting of administering a formulation according to protection factor 1 or a capsule according to protection factor 45 or protection factor 46.

49. The method according to protection factor 48, where the illness or injury is selected from a group that includes clinically high risk of psychosis, insomnia, first psychotic episode, psychosis in Parkinson's disease, schizophrenia, generalized anxiety disorder, social anxiety disorder, panic disorder, post-traumatic stress disorder, Alzheimer's disease, postpartum psychosis, agoraphobia, acute stress disorder, and schizoaffective disorder.

50. The method according to protection factor 49, where the illness or injury is clinically high risk of psychosis. 51- The method according to protection element 50, consists of giving the participant in the study the formula contained in protection element 12.52- The method according to protection element 49, where the illness or disorder is insomnia. 53- The method according to protection element 52, which consists of giving the study participant the formula listed in protection element 12.